Nothing Special   »   [go: up one dir, main page]

WO2009012907A1 - Synergistic fungicidal active genistein combinations - Google Patents

Synergistic fungicidal active genistein combinations Download PDF

Info

Publication number
WO2009012907A1
WO2009012907A1 PCT/EP2008/005746 EP2008005746W WO2009012907A1 WO 2009012907 A1 WO2009012907 A1 WO 2009012907A1 EP 2008005746 W EP2008005746 W EP 2008005746W WO 2009012907 A1 WO2009012907 A1 WO 2009012907A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
group
alkyl
phenyl
chlorine
Prior art date
Application number
PCT/EP2008/005746
Other languages
French (fr)
Inventor
Anne Suty-Heinze
Darren Mansfield
Original Assignee
Bayer Cropscience Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Cropscience Ag filed Critical Bayer Cropscience Ag
Publication of WO2009012907A1 publication Critical patent/WO2009012907A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • A01N43/14Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom six-membered rings
    • A01N43/16Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom six-membered rings with oxygen as the ring hetero atom

Definitions

  • the present invention relates to novel active compound combinations comprising firstly genistein and secondly further known fungicidally active compounds, which novel active compound combinations are highly suitable for controlling unwanted phytopathogenic fungi.
  • genistein is also a potent enhancer of the activity of fungicides. This enhancing effect is overadditive. This means that the fungicidal activity of the mixtures of genistein and the fungicides is higher than the sum of the fungicidal activities of the components alone.
  • salts of genistein can be mixed with active compounds, selected from groups (2) to (24), to give fungicidal mixtures with synergistic activities.
  • active compounds selected from groups (2) to (24)
  • these are alkali salts of genistein.
  • compositions that at least comprise:
  • A represents NH or O
  • a 3 represents N or CH
  • R 11 represents phenyl, phenoxy or pyridinyl, each of which is optionally mono- or disubstituted by identical or different substituents from the group consisting of chlorine, cyano, methyl and trifluoromethyl, or represents l-(4-chlorophenyl)-pyrazol-3-yl or represents 1 ,2-propanedione-bis(0-methyloxime)- 1 -y 1,
  • R 12 represents hydrogen or fluorine
  • n 0 or 1
  • R 13 represents hydrogen, fluorine, chlorine, phenyl or 4-chlorophenoxy
  • R 14 represents hydrogen or chlorine
  • a 4 represents a direct bond, -CH 2 -, -(CH 2 ) 2 - or -O-,
  • a 5 represents C or Si (silicon)
  • R 15 represents hydrogen, hydroxyl or cyano
  • R 16 represents 1-cyclopropylethyl, 1 -chlorocyclopropyl, Ci-Gj-alkyl, Ci-C 6 -hydroxyalkyl, d- C 4 -alkylcarbonyl, C r C 2 -haloalkoxy-Ci-C 2 -alkyl, trimethylsilyl-C r C 2 -alkyl, monofluorophenyl or phenyl,
  • R 15 and R 16 furthermore together represent -0-CH 2 -CH(R 18 )-O-, -O-CH 2 -CH(R 18 )-CH 2 -, or -O-CH-(2-chlorophenyl)-,
  • R 18 represents hydrogen, Ci-C 4 -alkyl or bromine
  • R 19 represents hydrogen or methyl
  • X represents 2-chloro-3-pyridinyl, represents 1 -methylpyrazol-4-yl which is substituted in the 3-position by methyl or trifluoromethyl and in the 5-position by hydrogen or chlorine, represents 4-ethyl-2-ethylamino-l,3-thiazol-5-yl, represents 1 -methyl-cyclohexyl, represents 2,2-dichloro-l-ethyl-3-methylcyclopropyl, represents 2-fluoro-2-propyl or represents phenyl which is mono- to trisubstituted by identical or different substituents from the group consisting of chlorine, methyl, and trifluoromethyl,
  • X furthermore represents 3,4-dichloroisothiazol-5-yl, 5,6-dihydro-2-methyl-l,4-oxathiin-3-yl, 4-methyl-l,2,3-thiadiazol-5-yl, 4,5-dimethyl-2-trimethylsilylthiophen-3-yl, 1 -methylpyrrol- 3-yl which is substituted in the 4-position by methyl or trifluoromethyl and in the 5-position by hydrogen or chlorine,
  • Y represents a direct bond, Ci-C 6 -alkanediyl (alkylene) which is optionally substituted by chlorine, cyano or oxo or represents thiophenediyl,
  • Y furthermore represents C 2 -C 6 -alkenediyl (alkenylene),
  • Z represents hydrogen or the group
  • Z furthermore represents Ci-C 6 -alkyl
  • a 6 represents CH or N
  • R 20 represents hydrogen, chlorine, phenyl which is optionally mono- or disubstituted by identical or different substituents from the group consisting of chlorine and di(d-C 3 - alkyl)aminocarbonyl,
  • R 20 furthermore represents cyano or C r C 6 -alkyl
  • R 21 represents hydrogen, chlorine, or 1 -methylethoxy
  • R 22 represents hydrogen, chlorine, hydroxyl, methyl or trifluoromethyl
  • R 22 furthermore represents di(C 1 -C 3 -alkyl)aminocarbonyl
  • R 20 and R 21 furthermore together represent *-CH(CH 3 )-CH 2 -C(CH 3 ) 2 - or *-CH(CH 3 )-O-C(CH 3 ) 2 - where the bond marked with * is attached to R 20 ;
  • R 1 represents hydrogen, halogen, Ci-C 3 -alkyl or Ci-C 3 -haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,
  • A represents one of the radicals Al to A8 below:
  • R 2 represents Ci-C3-alkyl
  • R 3 represents hydrogen, halogen, C r C 3 -alkyl or Ci-C 3 -haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,
  • R 4 represents hydrogen, halogen or Ci-C 3 -alkyl
  • R 5 represents halogen, C r C 3 -alkyl or C r C 3 -haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,
  • R 6 represents hydrogen, halogen, Ci-C 3 -alkyl, amino, mono- or di(Ci-C 3 -alkyl)amino,
  • R 7 represents hydrogen, halogen, Ci-C 3 -alkyl or Ci-C 3 -haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,
  • R 8 represents halogen, C r C 3 -alkyl or Ci-C 3 -haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,
  • R 9 represents halogen, Ci-C 3 -alkyl or C]-C 3 -haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,
  • R 10 represents hydrogen, halogen, CrdValkyl or Ci-C 3 -haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,
  • R 23 represents benzyl, furyl or methoxymethyl
  • R 24 represents methyl, cyclopropyl or 1-propynyl
  • R 25 and R 26 each represent hydrogen or together represent -O-CF 2 -O-,
  • R 27 represents hydrogen, Ci-C 4 -alkylaminocarbonyl or represents 3,5-dimethylisoxazol-4- ylsulphonyl,
  • R 28 represents chlorine, methoxycarbonylamino, chlorophenyl, furyl or thiazolyl
  • R 29 represents n- or isopropyl, methyl.
  • R 30 represents di(CrC 2 -alkyl)amino-C 2 -C 4 -alkyl, diethoxyphenyl, [2-Chloro-5-[(lE)-l-[[(6- methyl-2-pyridinyl)methoxy]imino]ethyl]phenyl]rnethyl or
  • R and R independently of one another represent hydrogen or methyl
  • R 33 represents Ci-C I4 -alkyl (preferably Ci 2 -Ci 4 -alkyl), C 5 -Ci 2 -cycloalkyl (preferably Ci 0 -Ci 2 - cycloalkyl), phenyl-Ci-C 4 -alkyl, which may be substituted in the phenyl moiety by halogen or Ci-C 4 -alkyl or represents acrylyl which is substituted by chlorophenyl and dimethoxyphenyl;
  • R 34 represents chlorine or cyano
  • R 35 represents chlorine or nitro
  • R 36 represents chlorine
  • R 35 and R 36 furthermore together represent -0-CF 2 -O-;
  • R 37 represents unsubstituted or fluorine-, chlorine-, bromine-, methyl- or ethyl-substituted phenyl, 2-naphthyl, 1 ,2,3,4-tetrahydronaphthyl or indanyl;
  • a 7 represents a direct bond or -O-
  • R 38 represents hydrogen or C r C 4 -alkyl
  • R 39 represents Ci-C 6 -alkyl;
  • R 40 represents Ci-C 6 -alkyl or C 2 -C 6 -alkenyl
  • R 41 represents Ci-C 6 -alkyl
  • R 40 and R 41 furthermore together represent C 4 -C 5 -alkanediyl (alkylene) which is mono- or disubstituted by Ci-C 6 -alkyl,
  • R 42 represents bromine or chlorine
  • R 43 and R 47 independently of one another represent hydrogen, fluorine, chlorine or methyl
  • R 44 and R 46 independently of one another represent hydrogen or fluorine
  • R 45 represents hydrogen, fluorine or methyl
  • R 48 represents C,-C 6 -alkyl
  • R 4y represents C r C 6 -alkyl, C 2 -C 6 -alkenyl or C 2 -C 6 -alkynyl;
  • R 50 represents hydrogen or fluorine
  • R 52 represents hydrogen, fluorine, chlorine, bromine, methyl or trifluoromethyl
  • Het represents one of the radicals Hetl to Het7 below:
  • R 53 represents iodine, methyl, difluoromethyl or trifluoromethyl
  • R 54 represents hydrogen, fluorine, chlorine or methyl
  • R 55 represents methyl, difluoromethyl or trifluoromethyl
  • R 56 represents chlorine, bromine, iodine, methyl, difluoromethyl or trifluoromethyl
  • R 57 represents methyl or trifluoromethyl.
  • the formula (II) embraces the following preferred mixing partners of group (2): (2-1) azoxystrobin (known from EP-A 0 382 375) of the formula
  • Preferred mixing partners of group (5) are (5-1) iprovalicarb (known from DE-A 40 26 966) of the formula
  • R 1 represents hydrogen, fluorine, chlorine, methyl, ethyl, n-, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monochloromethyl, dichloromethyl or trichloromethyl,
  • A represents one of the radicals Al to A5 below:
  • R 2 represents methyl, ethyl, n- or isopropyl
  • R 3 represents iodine, methyl, difluoromethyl or trifluoromethyl
  • R 4 represents hydrogen, fluorine, chlorine or methyl
  • R 5 represents chlorine, bromine, iodine, methyl, difluoromethyl or trifluoromethyl
  • R 6 represents hydrogen, chlorine, methyl, amino or dimethylamino
  • R 7 represents methyl, difluoromethyl or trifluoromethyl
  • R 8 represents bromine or methyl
  • R 9 represents methyl or trifluoromethyl
  • R 1 represents hydrogen, fluorine, chlorine, methyl, ethyl or trifluoromethyl
  • A represents one of the radicals Al or A2 below:
  • R 2 represents methyl or isopropyl
  • R 3 represents methyl, difluoromethyl or trifluoromethyl
  • R 4 represents hydrogen or fluorine
  • R 5 represents iodine, difluoromethyl or trifluoromethyl.
  • R represents hydrogen or methyl, represents one of the radicals Al or A2 below:
  • R represents methyl
  • R represents methyl
  • R 4 represents fluorine
  • R 5 represents iodine or trifluoromethyl.
  • R 1 , R 2 , R 3 and R 4 are as defined above.
  • Preferred mixing partners of group (7) are
  • Preferred mixing partners of group (12) are (12-1) captafol (known from US 3,178,447) of the formula
  • Preferred mixing partners of group (14) are:
  • the formula (X) embraces the following preferred mixing partners of group (15): (15-1) aldimorph (known from DD 140 041 ) of the formula
  • the formula (XII) embraces the following preferred mixing partners of group (18) which are known from WO 96/23793 and can in each case be present as E or Z isomers. Accordingly, compounds of the formula (XII) can be present as a mixture of different isomers or else in the form of a single isomer. Preference is given to compounds of the formula (XII) in the form of their E isomers:
  • Preferred mixing partners of group (19) are (19-1) acibenzolar-S-methyl (known from EP-A O 313 512) of the formula
  • Preferred mixing partners of group (20) are:
  • Preferred mixing partners of group (21) are (21-1) fenoxanil (known from EP-A 0 262 393) of the formula
  • Preferred mixing partners of group (22) are:
  • Preferred mixing partners of group (24) are:
  • compound (6-7) carpropamid, has three asymmetrically substituted carbon atoms. Accordingly, compound (6-7) can be present as a mixture of different isomers or else in the form of a single component. Particular preference is given to the compounds
  • Particularly preferred mixing partners are the following active compounds:
  • Very particularly preferred mixing partners are the following active compounds:
  • Preferred active compound combinations comprising two groups of active compounds and in each case at least genistein of the formula (I) and at least one active compound of the given group (2) to (24) are described below. These combinations are the active compound combinations A to U.
  • the active compound combinations A also comprise a strobilurin of the formula (II) (group 2)
  • active compound combinations A in which the strobilurin of the formula (II) (group 2) is selected from the list below:
  • the active compound combinations B also comprise a triazole of the formula (HT) (group 3)
  • the active compound combinations C also comprise a sulphenamide of the formula (IV) (group 4)
  • the active compound combinations D also comprise a valinamide (group 5) selected from
  • the active compound combinations E also comprise a carboxamide of the formula (V) (group 6)
  • the active compound combinations F also comprise a dithiocarbamate (group 7) selected from
  • the active compound combinations G also comprise an acylalanine of the formula (VI) (group 8)
  • active compound combinations G in which the acylalanine of the formula (VT) (group 8) is selected from the list below:
  • the active compound combinations H also comprise an anilinopyrimidine (group 9) selected from
  • the active compound combinations I also comprise a benzimidazole of the formula (VIQ) (group 10)
  • R 25 , R 26 , R 27 and R 28 are as defined above.
  • the active compound combinations J also comprise a carbamate (group 11) of the formula (IX)
  • the active compound combinations K also comprise a dicarboximide (group 12) selected from
  • the active compound combinations L also comprise a guanidine (group 13) selected from
  • the active compound combinations M also comprise an imidazole (group 14) selected from
  • the active compound combinations N also comprise a morpholine (group 15) of the formula (X)
  • the active compound combinations O also comprise a pyrrole (group 16) of the formula (XI)
  • R 34 , R 35 and R 36 are as defined above.
  • the active compound combinations P also comprise a phosphonate (group 17) selected from
  • the active compound combinations Q also comprise a fungicide (group 19) selected from
  • the active compound combinations R also comprise a (thio)urea derivative (group 20) selected from
  • the active compound combinations S also comprise a triazolopyrimidine (group 22) of the formula (XIV)
  • R 40 , R 41 , R 42 , R 43 , R 44 , R 45 , R 46 and R 47 are as defined above.
  • the active compound combinations T also comprise an iodochromone (group 23) of the formula (XV)
  • the active compound combinations U also comprise a biphenylcarboxamide (group 24) of the formula (XVI)
  • R 50 , R 51 , R 52 and Het are as defined above.
  • biphenylcarboxamide (group 24) of the formula (XVI) is selected from the list below: (24-1) N-(3 t ,4 1 -dichloro-5-fluoro-l,l'-biphenyl-2-yl)-3-(difluoromethyl)-l-methyl-lH-pyrazole-4- carboxamide
  • the active compound combinations according to the invention comprise at least one active compound from the compounds of groups (2) to (24). In addition, they may also comprise further fungicidally active additives.
  • the active compounds in the active compound combinations according to the invention are present in certain weight ratios, the synergistic effect is particularly pronounced.
  • the weight ratios of the active compounds in the active compound combinations can be varied within a relatively wide range.
  • the active compound combinations according to the invention comprise active genistein and a mixing partner from one of the groups (2) to (24) in the mixing ratios listed in an exemplary manner in Table 22 below.
  • the mixing ratios are based on ratios by weight. The ratio is to be understood as active compound genistein of the formula (T): mixing partner. Table 22: Mixing ratios
  • dithianon 50 1 to 1 :50 10: 1 to 1 :20
  • prothioconazole 10 1 to 1 : 10 14 1 : 1 to l:10 9

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Novel active compound combinations comprising genistein of formula (I) and the active compound groups (2) to (24) listed in the description have very good fungicidal properties.

Description

SYNERGISTIC FUNGICIDAL ACTIVE GENISTEIN COMBINATIONS
The present invention relates to novel active compound combinations comprising firstly genistein and secondly further known fungicidally active compounds, which novel active compound combinations are highly suitable for controlling unwanted phytopathogenic fungi.
Genistein of formula (I)
Figure imgf000002_0001
is an isoflavone that is known to have positive effects on the growth of agricultural crops (WO 2005/087005 Al).
It has now been discovered that genistein is also a potent enhancer of the activity of fungicides. This enhancing effect is overadditive. This means that the fungicidal activity of the mixtures of genistein and the fungicides is higher than the sum of the fungicidal activities of the components alone.
Besides Genistein, also salts of genistein can be mixed with active compounds, selected from groups (2) to (24), to give fungicidal mixtures with synergistic activities. Preferably, these are alkali salts of genistein.
The present invention describes compositions that at least comprise:
Genistein and at least one active compound selected from groups (2) to (24) below:
Group (2) Strobilurins of the general formula (II)
Figure imgf000002_0002
in which A1 represents one of the groups
Figure imgf000003_0001
A represents NH or O,
A3 represents N or CH,
L represents one of the groups
Figure imgf000003_0002
where the bond marked with an asterisk (*) is attached to the phenyl ring,
R11 represents phenyl, phenoxy or pyridinyl, each of which is optionally mono- or disubstituted by identical or different substituents from the group consisting of chlorine, cyano, methyl and trifluoromethyl, or represents l-(4-chlorophenyl)-pyrazol-3-yl or represents 1 ,2-propanedione-bis(0-methyloxime)- 1 -y 1,
R12 represents hydrogen or fluorine;
Group (3) Triazoles of the general formula (IIP
Figure imgf000003_0003
in which Q represents hydrogen or SH,
m represents 0 or 1 ,
R13 represents hydrogen, fluorine, chlorine, phenyl or 4-chlorophenoxy,
R14 represents hydrogen or chlorine,
A4 represents a direct bond, -CH2-, -(CH2)2- or -O-,
A4 furthermore represents *-CH2-CHR17- or *-CH=CR17-, where the bond marked with * is attached to the phenyl ring, in which case R15 and R17 together represent -CH2-CH2- CH[CH(CH3);,]- or -CH2-CH2-C(CH3);,-,
A5 represents C or Si (silicon),
A4 further represents -N(R17)- and A5 furthermore together with R15 and R16 represents the group C=N-R18, in which case R17 and R18 together represent the group
, where the bond marked with * is attached to R17,
Figure imgf000004_0001
R15 represents hydrogen, hydroxyl or cyano,
R16 represents 1-cyclopropylethyl, 1 -chlorocyclopropyl, Ci-Gj-alkyl, Ci-C6-hydroxyalkyl, d- C4-alkylcarbonyl, CrC2-haloalkoxy-Ci-C2-alkyl, trimethylsilyl-CrC2-alkyl, monofluorophenyl or phenyl,
R15 and R16 furthermore together represent -0-CH2-CH(R18)-O-, -O-CH2-CH(R18)-CH2-, or -O-CH-(2-chlorophenyl)-,
R18 represents hydrogen, Ci-C4-alkyl or bromine; or
Imibenconazole of the formula
Figure imgf000005_0001
Group (4) Sulphenamides of the general formula (FV)
Figure imgf000005_0002
in which R19 represents hydrogen or methyl;
Group (5) Valinamides selected from
(5-1) iprovalicarb
(5-2) N'-[2-(4-{[3-(4-chlorophenyl)-2-propynyl]oxy}-3-methoxyphenyl)ethyl]-N2- (methylsulphonyl)-D-valinamide
(5-3) benthiavalicarb Group (6) Carboxamides of the general formula ("V)
Figure imgf000006_0001
in which
X represents 2-chloro-3-pyridinyl, represents 1 -methylpyrazol-4-yl which is substituted in the 3-position by methyl or trifluoromethyl and in the 5-position by hydrogen or chlorine, represents 4-ethyl-2-ethylamino-l,3-thiazol-5-yl, represents 1 -methyl-cyclohexyl, represents 2,2-dichloro-l-ethyl-3-methylcyclopropyl, represents 2-fluoro-2-propyl or represents phenyl which is mono- to trisubstituted by identical or different substituents from the group consisting of chlorine, methyl, and trifluoromethyl,
X furthermore represents 3,4-dichloroisothiazol-5-yl, 5,6-dihydro-2-methyl-l,4-oxathiin-3-yl, 4-methyl-l,2,3-thiadiazol-5-yl, 4,5-dimethyl-2-trimethylsilylthiophen-3-yl, 1 -methylpyrrol- 3-yl which is substituted in the 4-position by methyl or trifluoromethyl and in the 5-position by hydrogen or chlorine,
Y represents a direct bond, Ci-C6-alkanediyl (alkylene) which is optionally substituted by chlorine, cyano or oxo or represents thiophenediyl,
Y furthermore represents C2-C6-alkenediyl (alkenylene),
Z represents hydrogen or the group
Figure imgf000006_0002
Z furthermore represents Ci-C6-alkyl,
A6 represents CH or N, R20 represents hydrogen, chlorine, phenyl which is optionally mono- or disubstituted by identical or different substituents from the group consisting of chlorine and di(d-C3- alkyl)aminocarbonyl,
R20 furthermore represents cyano or CrC6-alkyl,
R21 represents hydrogen, chlorine, or 1 -methylethoxy
R22 represents hydrogen, chlorine, hydroxyl, methyl or trifluoromethyl,
R22 furthermore represents di(C1-C3-alkyl)aminocarbonyl,
R20 and R21 furthermore together represent *-CH(CH3)-CH2-C(CH3)2- or *-CH(CH3)-O-C(CH3)2- where the bond marked with * is attached to R20;
Group (6a) Carboxamides of the general formula (Va)
Figure imgf000007_0001
in which
R1 represents hydrogen, halogen, Ci-C3-alkyl or Ci-C3-haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,
A represents one of the radicals Al to A8 below:
Figure imgf000007_0002
Figure imgf000008_0001
R2 represents Ci-C3-alkyl,
R3 represents hydrogen, halogen, CrC3-alkyl or Ci-C3-haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,
R4 represents hydrogen, halogen or Ci-C3-alkyl,
R5 represents halogen, CrC3-alkyl or CrC3-haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,
R6 represents hydrogen, halogen, Ci-C3-alkyl, amino, mono- or di(Ci-C3-alkyl)amino,
R7 represents hydrogen, halogen, Ci-C3-alkyl or Ci-C3-haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,
R8 represents halogen, CrC3-alkyl or Ci-C3-haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,
R9 represents halogen, Ci-C3-alkyl or C]-C3-haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,
R10 represents hydrogen, halogen, CrdValkyl or Ci-C3-haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,
Group (6b) Carboxamides
(6b- 1) Thifluzamide (CII not covered by genral formula V)
Figure imgf000009_0001
(6b-2) N-(2-[ 1 , 1 '-bicyclopropyl]-2-ylpheny l)-3-(difluoromethyl)- 1 -methyl- 1 H-pyrazole-4- carboxamide
Figure imgf000009_0002
(6b-2)
with preference of the following two stereoisomers
Figure imgf000009_0003
(6b-2b) Group (7) Dithiocarbamates selected from
(7-1) mancozeb (7-2) maneb (7-3) metiram (7-4) propineb (7-5) thiram (7-6) zineb (7-7) ziram Group (8) Acylalanines of the general formula (VD
Figure imgf000010_0001
in which marks a carbon atom in the R or the S configuration, preferably in the S configuration,
R23 represents benzyl, furyl or methoxymethyl;
Group (9): Anilinopyrimidines of the general formula (VID
Figure imgf000010_0002
in which R24 represents methyl, cyclopropyl or 1-propynyl;
Group (10): Benzimidazoles of the general formula (VHP
Figure imgf000011_0001
in which
R25 and R26 each represent hydrogen or together represent -O-CF2-O-,
R27 represents hydrogen, Ci-C4-alkylaminocarbonyl or represents 3,5-dimethylisoxazol-4- ylsulphonyl,
R28 represents chlorine, methoxycarbonylamino, chlorophenyl, furyl or thiazolyl;
Group (11): Carbamates of the general formula (DO
Figure imgf000011_0002
in which
R29 represents n- or isopropyl, methyl.
R30 represents di(CrC2-alkyl)amino-C2-C4-alkyl, diethoxyphenyl, [2-Chloro-5-[(lE)-l-[[(6- methyl-2-pyridinyl)methoxy]imino]ethyl]phenyl]rnethyl or
salts of these compounds being included;
Group (12): Dicarboximides selected from
(12-1) captafol
(12-2) captan (12-3) folpet
(12-4) iprodione
(12-5) procymidone
(12-6) vinclozolin Group (13): Guanidines selected from
(13-1) dodine
(13-2) guazatine
(13-3) iminoctadine triacetate
(13-4) iminoctadine tris(albesilate) Group (14): Imidazoles selected from
(14-1) cyazofamid
(14-2) prochloraz
(14-3) triazoxide
(14-4) pefurazoate Group (15): Morpholines of the general formula (X)
Figure imgf000012_0001
in which
R and R independently of one another represent hydrogen or methyl, R33 represents Ci-CI4-alkyl (preferably Ci2-Ci4-alkyl), C5-Ci2-cycloalkyl (preferably Ci0-Ci2- cycloalkyl), phenyl-Ci-C4-alkyl, which may be substituted in the phenyl moiety by halogen or Ci-C4-alkyl or represents acrylyl which is substituted by chlorophenyl and dimethoxyphenyl;
Group (16): Pyrroles of the general formula (XD
Figure imgf000013_0001
in which
R34 represents chlorine or cyano,
R35 represents chlorine or nitro,
R36 represents chlorine,
R35 and R36 furthermore together represent -0-CF2-O-;
Group (17): Phosphonates selected from
(17-1) fosetyl-Al
(17-2) phosphonic acid;
Group (18): Phenylethanamides of the general formula (XID
Figure imgf000013_0002
in which R37 represents unsubstituted or fluorine-, chlorine-, bromine-, methyl- or ethyl-substituted phenyl, 2-naphthyl, 1 ,2,3,4-tetrahydronaphthyl or indanyl;
Group (19): Fungicides selected from
(19-1) acibenzolar-S-methyl (19-2) chlorothalonil
(19-3) cymoxanil
(19-4) edifenphos
(19-5) famoxadone
(19-6) fluazinam (19-7) copper oxychloride
(19-8) copper hydroxide
(19-9) oxadixyl
(19-10) spiroxamine
(19-l l) dithianon (19-12) metrafenone
(19-13) fenamidone
(19-14) 2,3-dibutyl-6-chlorothieno[2,3-d]pyrimidin-4(3H)-one
(19-15) probenazole
(19-16) isoprothiolane (19-17) kasugamyc in (19-18) phthalide
(19-19) ferimzone
(19-20) tricyclazole
(19-21 ) N-( {4-[(cyclopropylamino)carbonyl]phenyl} sulphonyl)-2-methoxybenzamide
(19-22) 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-l-yloxy)phenyl]ethyl}-2-(prop-2-yn-l- yloxy)acetamide
(19-23) Diclomezine of the formula
Figure imgf000015_0001
(19-24) Hymexazole of the formula
Figure imgf000015_0002
(19-25) Iprobenfos of the formula
Figure imgf000015_0003
(19-26) Triflumizole of the formula
Figure imgf000016_0001
Group (20): (Thiourea derivatives selected from (20-1) pencycuron (20-2) thiophanate-methyl (20-3) thiophanate-ethyl
Group (21): Amides of the general formula (XIID
Figure imgf000016_0002
in which
A7 represents a direct bond or -O-, A8 represents -C(O)NH- or -NHC(=0)-,
R38 represents hydrogen or CrC4-alkyl,
R39 represents Ci-C6-alkyl; Group (22): Triazolopyrimidines of the general formula (XTV)
Figure imgf000017_0001
in which
R40 represents Ci-C6-alkyl or C2-C6-alkenyl,
R41 represents Ci-C6-alkyl,
R40 and R41 furthermore together represent C4-C5-alkanediyl (alkylene) which is mono- or disubstituted by Ci-C6-alkyl,
R42 represents bromine or chlorine,
R43 and R47 independently of one another represent hydrogen, fluorine, chlorine or methyl,
R44 and R46 independently of one another represent hydrogen or fluorine,
R45 represents hydrogen, fluorine or methyl,
Group (23): Iodochromones of the general formula (XV")
Figure imgf000017_0002
in which
R48 represents C,-C6-alkyl,
R4y represents CrC6-alkyl, C2-C6-alkenyl or C2-C6-alkynyl; Group (24): Biphenylcarboxamides of the general formula (XVD
Figure imgf000018_0001
in which
R50 represents hydrogen or fluorine,
R51 represents fluorine, chlorine, bromine, methyl, trifluoromethyl, trifluoromethoxy, -CH=N-OMe or -C(Me)=N-OMe,
R52 represents hydrogen, fluorine, chlorine, bromine, methyl or trifluoromethyl,
Het represents one of the radicals Hetl to Het7 below:
Figure imgf000018_0002
Hetl Het2 Het3 Het4 Het5 Het6 Het7
R53 represents iodine, methyl, difluoromethyl or trifluoromethyl,
R54 represents hydrogen, fluorine, chlorine or methyl,
R55 represents methyl, difluoromethyl or trifluoromethyl,
R56 represents chlorine, bromine, iodine, methyl, difluoromethyl or trifluoromethyl,
R57 represents methyl or trifluoromethyl.
The formula (II) embraces the following preferred mixing partners of group (2): (2-1) azoxystrobin (known from EP-A 0 382 375) of the formula
Figure imgf000019_0001
(2-2) fluoxastrobin (known from DE-A 196 02 095) of the formula
Figure imgf000019_0002
(2-3) (2E)-2-(2-{[6-(3-chloro-2-methylphenoxy)-5-fluoro-4-pyrimidinyl]oxy}phenyl)-2-
(methoxyimino)-N-methylethanamide (known from DE-A 196 46 407, EP-B 0 712 396) of the formula
Figure imgf000019_0003
(2-4) trifloxystrobin (known from EP-A 0 460 575) of the formula
Figure imgf000019_0004
(2-5) (2£)-2-(methoxyimino)-N-methyl-2-(2-{[({(l£)-l-[3-(trifluoromethyl)phenyl]ethyliden}- amino)oxy]methyl}phenyl)ethanamide (known from EP-A 0 569 384) of the formula
Figure imgf000020_0001
(2-6) (2£)-2-(methoxyimino)-N-methyl-2-{2-[(£)-({ l-[3-
(trifluoromethyl)phenyl)ethoxy}imino)methyl]phenyl}ethanamide (known from EP-A 0 596 254) of the formula
Figure imgf000020_0002
(2-7) orysastrobin (known from DE-A 195 39 324) of the formula
Figure imgf000020_0003
(2-8) 5-methoxy-2-methyl-4-(2-{ [( {( IE)- 1 -[3-(trifluoromethy l)phenyl]ethyliden} amino)oxy]- methyl}phenyl)-2,4-dihydro-3H-l,2,4-triazol-3-one (known from WO 98/23155) of the formula
Figure imgf000020_0004
(2-9) kresoxim-methyl (known from EP-A 0 253 213) of the formula
Figure imgf000021_0001
(2-10) dimoxystrobin (known from EP-A 0 398 692) of the formula
Figure imgf000021_0002
(2-11) picoxystrobin (known from EP-A 0 278 595) of the formula
Figure imgf000021_0003
(2-12) pyraclostrobin (known from DE-A 44 23 612) of the formula
Figure imgf000021_0004
(2-13) metominostrobin (known from EP-A 0 398 692) of the formula
Figure imgf000021_0005
The formula (III) embraces the following preferred mixing partners of group (3): (3-1) azaconazole (known from DE-A 25 51 560) of the formula
Figure imgf000022_0001
(3-2) etaconazole (known from DE-A 25 51 560) of the formula
Figure imgf000022_0002
(3-3) propiconazole (known from DE-A 25 51 560) of the formula
Figure imgf000022_0003
(3-4) difenoconazole (known from EP-A 0 112 284) of the formula
Figure imgf000022_0004
(3-5) bromuconazole (known from EP-A 0 258 161) of the formula
Figure imgf000023_0001
(3-6) cyproconazole (known from DE-A 34 06 993) of the formula
Figure imgf000023_0002
(3-7) hexaconazole (known from DE-A 30 42 303) of the formula
Figure imgf000023_0003
(3-8) penconazole (known from DE-A 27 35 872) of the formula
Figure imgf000023_0004
(3-9) myclobutanil (known from EP-A 0 145 294) of the formula
Figure imgf000024_0001
(3-10) tetraconazole (known from EP-A 0 234 242) of the formula
Figure imgf000024_0002
(3-11) flutriafol (known from EP-A 0 015 756) of the formula
Figure imgf000024_0003
(3-12) epoxiconazole (known from EP-A 0 196 038) of the formula
Figure imgf000024_0004
(3-13) flusilazole (known from EP-A 0 068 813) of the formula
Figure imgf000025_0001
(3-14) simeconazole (known from EP-A 0 537 957) of the formula
Figure imgf000025_0002
(3-15) prothioconazole (known from WO 96/16048) of the formula
Figure imgf000025_0003
(3-16) fenbuconazole (known from DE-A 37 21 786) of the formula
Figure imgf000025_0004
(3-17) tebuconazole (known from EP-A 0 040 345) of the formula
Figure imgf000026_0001
(3-18) ipconazole (known from EP-A 0 329 397) of the formula
Figure imgf000026_0002
(3-19) metconazole (known from EP-A 0 329 397) of the formula
Figure imgf000026_0003
(3-20) triticonazole (known from EP-A 0 378 953) of the formula
Figure imgf000026_0004
(3-21) bitertanol (known from DE-A 23 24 010) of the formula
Figure imgf000027_0001
(3-22) triadimenol (known from DE-A 23 24 010) of the formula
Figure imgf000027_0002
(3-23) triadimefon (known from DE-A 22 01 063) of the formula
Figure imgf000027_0003
(3-24) fluquinconazole (known from EP-A 0 183 458) of the formula
Figure imgf000027_0004
(3-25) quinconazole (known from EP-A 0 183 458) of the formula
Figure imgf000027_0005
(3-26) Diclobutrazole of the formula
Figure imgf000028_0001
(3-27) Diniconazole of the formula
Figure imgf000028_0002
The formula (FV) embraces the following preferred mixing partners of group (4):
(4-1) dichlofluanid (known from DE-A 11 93 498) of the formula
Figure imgf000028_0003
(4-2) tolylfluanid (known from DE-A 11 93 498) of the formula
Figure imgf000028_0004
Preferred mixing partners of group (5) are (5-1) iprovalicarb (known from DE-A 40 26 966) of the formula
Figure imgf000029_0001
(5-3) benthiavalicarb (known from WO 96/04252) of the formula
Figure imgf000029_0002
The formula (V) embraces the following preferred mixing partners of group (6):
(6-1) 2-chloro-N-(l,l,3-trimethylindan-4-yl)nicotinamide (known from EP-A 0256 503) of the formula
Figure imgf000029_0003
(6-2) boscalid (known from DE-A 195 31 813) of the formula
Figure imgf000029_0004
(6-3) furametpyr (known from EP-A 0 315 502) of the formula
Figure imgf000030_0001
(6-4) N-(3-p-tolylthiophen-2-yl)-l-methyl-3-trifluoromethyl-lH-pyrazole-4-carboxamide
(known from EP-A 0 737 682) of the formula
Figure imgf000030_0002
(6-5) ethaboxam (known from EP-A 0 639 574) of the formula
Figure imgf000030_0003
(6-6) fenhexamid (known from EP-A 0 339 418) of the formula
Figure imgf000030_0004
(6-7) carpropamid (known from EP-A 0 341 475) of the formula
Figure imgf000031_0001
(6-8) 2-chloro-4-(2-fluoro-2-methylpropionylamino)-N,N-dimethylbenzamide
(known from EP-A 0 600 629) of the formula
Figure imgf000031_0002
(6-9) picobenzamid (known from WO 99/42447) of the formula
Figure imgf000031_0003
(6-10) zoxamide (known from EP-A 0 604 019) of the formula
Figure imgf000031_0004
(6-1 1) 3,4-dichloro-N-(2-cyanophenyl)isothiazole-5-carboxamide (Isothianil) (known from WO 99/24413) of the formula
Figure imgf000031_0005
(6-12) carboxin (known from US 3,249,499) of the formula
Figure imgf000032_0001
(6-13) tiadinil (known from US 6,616,054) of the formula
Figure imgf000032_0002
(6-14) penthiopyrad (known from EP-A 0 737 682) of the formula
Figure imgf000032_0003
(6-15) silthiofam (known from WO 96/18631) of the formula
Figure imgf000032_0004
(6-16) N-[2-(l ,3-dimethylbutyl)phenyl]-l-methyl-4-(trifluoromethyl)-lH-pyrrole-3-carboxamide (known from WO 02/38542) of the formula
Figure imgf000032_0005
(6-17) N-{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}-2-(trifluoromethyl)benzamide (known from WO04016088)
Figure imgf000033_0001
(6-18) flutolanil of the formula
Figure imgf000033_0002
(6b-2) N-(2-[l,l'-bicyclopropyl]-2-ylphenyl)-3-(difluoromethyl)-l-methyl-lH-pyrazole-4- carboxamide
The formula (Va) embraces the following preferred mixing partners of group (6a):
R1 represents hydrogen, fluorine, chlorine, methyl, ethyl, n-, isopropyl, monofluoromethyl, difluoromethyl, trifluoromethyl, monochloromethyl, dichloromethyl or trichloromethyl,
A represents one of the radicals Al to A5 below:
Figure imgf000033_0003
R2 represents methyl, ethyl, n- or isopropyl,
R3 represents iodine, methyl, difluoromethyl or trifluoromethyl,
R4 represents hydrogen, fluorine, chlorine or methyl, R5 represents chlorine, bromine, iodine, methyl, difluoromethyl or trifluoromethyl,
R6 represents hydrogen, chlorine, methyl, amino or dimethylamino,
R7 represents methyl, difluoromethyl or trifluoromethyl,
R8 represents bromine or methyl, R9 represents methyl or trifluoromethyl.
Particular preference is given to carboxamides of the formula (Va) in which
R1 represents hydrogen, fluorine, chlorine, methyl, ethyl or trifluoromethyl,
A represents one of the radicals Al or A2 below:
Figure imgf000034_0001
R2 represents methyl or isopropyl,
R3 represents methyl, difluoromethyl or trifluoromethyl,
R4 represents hydrogen or fluorine,
R5 represents iodine, difluoromethyl or trifluoromethyl.
Verv particular preference is given to carboxamides of the formula (Va) in which
R represents hydrogen or methyl, represents one of the radicals Al or A2 below:
Figure imgf000035_0001
R represents methyl,
R represents methyl,
R4 represents fluorine,
R5 represents iodine or trifluoromethyl.
Very particular preference is given to using, in mixtures, compounds of the formula (Va)
Figure imgf000035_0002
in which R1, R2, R3 and R4 are as defined above.
Very particular preference is given to using, in mixtures, compounds of the formula (Vb)
(Va-2)
Figure imgf000035_0003
in which R1 and R5 are as defined above.
The formula (Va) embraces in particular the following preferred mixing partners of group (6a):
(6a-l) (Val-l)N-[2-(l,3-dimethylbutyl)phenyl]-l,3-dimethyl-lH-pyrazole-4-carboxamide
(6a-2) N-[2-(l ,3-dimethylbutyl)phenyl]-5-fluoro-l ,3-dimethyl-lH-pyrazole-4-carboxamide (pyflufen)
(known from WO 03/010149)
(6a-3) N-[2-(l,3-dimethylbutyl)phenyl]-5-chloro-l ,3-dimethyl-lH-pyrazole-4-carboxamide
(known from JP-A 10-251240)
(6a-4) 3-(difluoromethyl)-N-[2-(l,3-dimethylbutyl)phenyl]-l-methyl-lH-pyrazole-4-carboxamide
(6a-5) 3-(trifluoromethyl)-N-[2-(l,3-dimethylbutyl)phenyl]-5-fluoro-l-methyl-lH-pyrazole-4- carboxamide (known from DE-A 103 03 589)
(6a-6) 3-(trifluoromethyl)-N-[2-(l,3-dimethylbutyl)phenyl]-5-chloro-l-methyl-lH-pyrazole-4- carboxamide (known from JP-A 10-251240)
(6a-7) 1 ,3-dimethyl-N-[2-(l ,3,3-trimethylbutyl)phenyl]-lH-pyrazole-4-carboxamide
(known from JP-A 10-251240)
(6a-8) 5-fluoro-l ,3-dimethyl-N-[2-(l ,3,3-trimethylbutyl)phenyl]-lH-pyrazole-4-carboxamide
(known from WO 03/010149)
(6a-9) 3-(difluoromethyl)-l-methyl-N-[2-(l,3,3-trimethylbutyl)phenyl]-lH-pyrazole-4- carboxamide
(6a- 10) 3 -(trifluoromethy I)- 1 -methy l-N-[2-( 1 ,3 ,3 -trimethy lbuty l)pheny I]- 1 H-pyrazole-4- carboxamide (6a-l l) 3-(trifluoromethyl)-5-fluoro-l-methyl-N-[2-(l,3,3-trimethylbutyl)phenyl]-lH-pyrazole-4- carboxamide (known from DE-A 103 03 589)
(6a-12) 3-(trifluoromethyl)-5-chloro-l-methyl-N-[2-(l,3,3-trimethylbutyl)phenyl]-lH-pyrazole-4- carboxamide (known from JP-A 10-251240)
The formula (Vb) embraces in particular the following preferred mixing partners of group (6a):
(6a-13) N-[2-(l,3-dimethylbutyl)phenyl]-2-iodobenzamide
(known from DE-A 102 29 595)
(6a-14) 2-iodo-N-[2-(l,3,3-trimethylbutyl)phenyl]benzamide
(known from DE-A 102 29 595)
(6a-15) N-[2-(l,3-dimethylbutyl)phenyl]-2-(trifluoromethyl)benzamide
(known from DE-A 102 29 595)
(6a-l 6) 2-(trifluoromethyl)-N-[2-(l ,3,3-trimethylbutyl)phenyl]benzamide
(known from DE-A 102 29 595)
Preferred mixing partners of group (7) are
(7-1 ) mancozeb (known from DE-A 12 34 704) having the IUPAC name
manganese ethylenebis(dithiocarbamate) (polymeric) complex with zinc salt
(7-2) maneb (known from US 2,504,404) of the formula
Figure imgf000037_0001
(7-3) metiram (known from DE-A 10 76 434) having the IUPAC name zinc ammoniate ethylenebis(dithiocarbamate)-poly(ethylenethiuram disulphide)
(7-4) propineb (known from GB 935 981) of the formula
Figure imgf000038_0001
(7-5) ihiram (known from US 1 ,9/2,961 ) of the formula
Figure imgf000038_0002
(7-6) zineb (known from DE-A 10 81 446) of the formula
Figure imgf000038_0003
(7-7) ziram (known from US 2,588,428) of the formula
Figure imgf000038_0004
The formula (VI) embraces the following preferred mixing partners of group (8):
(8-1) benalaxyl (known from DE-A 29 03 612) of the formula
Figure imgf000039_0001
(8-2) furalaxyl (known from DE-A 25 13 732) of the formula
Figure imgf000039_0002
(8-3) metalaxyl (known from DE-A 25 15 091) of the formula
Figure imgf000039_0003
(8-4) metalaxyl-M (known from WO 96/01559) of the formula
Figure imgf000039_0004
(8-5) benalaxyl-M of the formula
Figure imgf000039_0005
The formula (VII) embraces the following preferred mixing partners of group (9): (9-1) cyprodinil (known from EP-A 0 310 550) of the formula
Figure imgf000040_0001
(9-2) mepanipyrim (known from EP-A 0 270 111) of the formula
Figure imgf000040_0002
(9-3) pyrimethanil (known from DD 151 404) of the formula
Figure imgf000040_0003
The formula (VIII) embraces the following preferred mixing partners of group (10):
(10-1) 6-chloro-5-[(3,5-dimethylisoxazol-4-yl)sulphonyl]-2,2-difluoro-5H-[l,3]dioxolo[4,5-fJ- benzimidazole (known from WO 97/06171) of the formula
Figure imgf000040_0004
(10-2) benomyl (known from US 3,631,176) of the formula
Figure imgf000041_0001
(10-3) carbendazim (known from US 3,010,968) of the formula
Figure imgf000041_0002
(10-4) chlorfenazole of the formula
Figure imgf000041_0003
(10-5) fuberidazole (known from DE-A 12 09 799) of the formula
Figure imgf000041_0004
(10-6) thiabendazole (known from US 3,206,468) of the formula
Figure imgf000041_0005
The formula (IX) embraces the following preferred mixing partners of group (11):
(1 1-1) diethofencarb (known from EP-A 0 078 663) of the formula
Figure imgf000041_0006
(11-2) propamocarb (known from US 3,513,241) of the formula
Figure imgf000042_0001
(11-3) propamocarb-hydrochloride (known from US 3,513,241) of the formula
Figure imgf000042_0002
(11-4) propamocarb-fosetyl of the formula
Figure imgf000042_0003
(11-5) pyribencarb of the formula
Figure imgf000042_0004
Preferred mixing partners of group (12) are (12-1) captafol (known from US 3,178,447) of the formula
Figure imgf000042_0005
(12-2) captan (known from US 2,553,770) of the formula
Figure imgf000043_0001
(12-3) folpet (known from US 2,553,770) of the formula
Figure imgf000043_0002
(12-4) iprodione (known from DE-A 21 49 923) of the formula
Figure imgf000043_0003
(12-5) procymidone (known from DE-A 20 12 656) of the formula
Figure imgf000043_0004
(12-6) vinclozolin (known from DE-A 22 07 576) of the formula
Figure imgf000043_0005
Preferred mixing partners of group (13) are
(13-1) dodine (known from GB 1 1 03 989) of the formula
Figure imgf000044_0001
(13-2) guazatine (known from GB 11 14 155) (13-3) iminoctadine triacetate (known from EP-A 0 155 509) of the formula
Figure imgf000044_0002
Preferred mixing partners of group (14) are
(14-1) cyazofamid (known from EP-A 0 298 196) of the formula
Figure imgf000044_0003
(14-2) prochloraz (known from DE-A 24 29 523) of the formula
Figure imgf000044_0004
(14-3) triazoxide (known from DE-A 28 02 488) of the formula
Figure imgf000045_0001
(14-4) pefurazoate (known from EP-A 0 248 086) of the formula
Figure imgf000045_0002
The formula (X) embraces the following preferred mixing partners of group (15): (15-1) aldimorph (known from DD 140 041 ) of the formula
Figure imgf000045_0003
(15-2) tridemorph (known from GB 988 630) of the formula
Figure imgf000045_0004
(15-3) dodemorph (known from DE-A 25 432 79) of the formula
Figure imgf000045_0005
(15-4) fenpropimorph (known from DE-A 26 56 747) of the formula
Figure imgf000046_0001
(15-5) dimethomorph (known from EP-A 0 219 756) of the formula
Figure imgf000046_0002
The formula (XI) embraces the following preferred mixing partners of group (16):
(16-1) fenpiclonil (known from EP-A 0 236 272) of the formula
C
Figure imgf000046_0003
(16-2) fludioxonil (known from EP-A 0 206 999) of the formula
Figure imgf000046_0004
(16-3) pyrrolnitrin (known from JP 65-25876) of the formula
Figure imgf000047_0001
Preferred mixing partners of group (17) are
(17-1) fosetyl-Al (known from DE-A 24 56 627) of the formula
Figure imgf000047_0002
(17-2) phosphonic acid (known chemical) of the formula
Figure imgf000047_0003
The formula (XII) embraces the following preferred mixing partners of group (18) which are known from WO 96/23793 and can in each case be present as E or Z isomers. Accordingly, compounds of the formula (XII) can be present as a mixture of different isomers or else in the form of a single isomer. Preference is given to compounds of the formula (XII) in the form of their E isomers:
(18-1) the compound 2-(2,3-dihydro-lH-inden-5-yl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2- (methoxyimino)acetamide of the formula
Figure imgf000047_0004
(18-2) the compound N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(methoxyimino)-2 -(5,6,7, 8-tetrahydro- naphthalen-2-yl)acetamide of the formula
Figure imgf000048_0001
(18-3) the compound 2-(4-chlorophenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(methoxyimino)- acetamide of the formula
Figure imgf000048_0002
(18-4) the compound 2-(4-bromophenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(methoxyimino)- acetamide of the formula
Figure imgf000048_0003
(18-5) the compound 2-(4-methylphenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(methoxyimino)- acetamide of the formula
Figure imgf000048_0004
(18-6) the compound 2-(4-ethylphenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(methoxyirnino)- acetamide of the formula
Figure imgf000049_0001
Preferred mixing partners of group (19) are (19-1) acibenzolar-S-methyl (known from EP-A O 313 512) of the formula
Figure imgf000049_0002
(19-2) chlorothalonil (known from US 3,290,353) of the formula
Figure imgf000049_0003
(19-3) cymoxanil (known from DE-A 23 12 956) of the formula
Figure imgf000049_0004
(19-4) edifenphos (known from DE-A 14 93 736) of the formula
Figure imgf000049_0005
(19-5) famoxadone (known from EP-A 0 393 911) of the formula
Figure imgf000050_0001
(19-6) fluazinam (known from EP-A 0 031 257) of the formula
Figure imgf000050_0002
(19-7) copper oxychloride
(19-9) oxadixyl (known from DE-A 30 30 026) of the formula
Figure imgf000050_0003
(19-10) spiroxamine (known from DE-A 37 35 555) of the formula
Figure imgf000050_0004
(19-11) dithianon (known from JP-A 44-29464) of the formula
Figure imgf000050_0005
(19-12) metrafenone (known from EP-A 0 897 904) of the formula
Figure imgf000051_0001
(19-13) fenamidone (known from EP-A 0 629 616) of the formula
Figure imgf000051_0002
(19-14) 2,3-dibutyl-6-chlorothieno[2,3-d]pyrimidin-4(3H)one (known from WO 99/14202) of the formula
Figure imgf000051_0003
(19-15) probenazole (known from US 3,629,428) of the formula
Figure imgf000051_0004
(19-16) isoprothiolane (known from US 3,856,814) of the formula
Figure imgf000051_0005
(19-17) kasugamycin (known from GB 1 094 567) of the formula
Figure imgf000052_0001
(19-18) phthalide (known from JP-A 57-55844) of the formula
Figure imgf000052_0002
(19-19) ferimzone (known from EP-A 0 019 450) of the formula
Figure imgf000052_0003
(19-20) tricyclazole (known from DE-A 22 50 077) of the formula
Figure imgf000052_0004
(19-21) N-({4-[(cyclopropylamino)carbonyl]phenyl}sulphonyl)-2-methoxybenzamide of the formula
Figure imgf000052_0005
( 19-22) 2-(4-chloropheny I)-N- {2-[3-methoxy-4-(prop-2-yn- 1 -y loxy)phenyl]ethyl} -2-(prop-2-yn- l-yloxy)acetamide (known from WO 01/87822) of the formula
Figure imgf000053_0001
Preferred mixing partners of group (20) are
(20-1) pencycuron (known from DE-A 27 32 257) of the formula
Figure imgf000053_0002
(20-2) thiophanate-methyl (known from DE-A 18 06 123) of the formula
Figure imgf000053_0003
(20-3) thiophanate-ethyl (known from DE-A 18 06 123) of the formula
Figure imgf000053_0004
Preferred mixing partners of group (21) are (21-1) fenoxanil (known from EP-A 0 262 393) of the formula
Figure imgf000053_0005
(21-2) diclocymet (known from JP-A 7-206608) of the formula
Figure imgf000054_0001
Preferred mixing partners of group (22) are
(22-1) 5-chloro-N-[f/5J-2,2,2-trifluoro-l-methylethyl]-6-(2,4,6-trifluorophenyl)[l,2,4]triazolo- [l,5-a]pyrimidine-7-amine (known from US 5,986,135) of the formula
Figure imgf000054_0002
(22-2) 5-chloro-N-[^R>l,2-dimethylpropyl]-6-(2,4,6-trifluorophenyl)[l,2,4]triazolo[l,5-a]- pyrimidine-7-amine (known from WO 02/38565) of the formula
Figure imgf000054_0003
(22-3) 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4-methylpiperidin- 1 -yl)[ 1 ,2,4]triazolo[ 1 ,5-a]- pyrimidine (known from US 5,593,996) of the formula
Figure imgf000055_0001
(22-4) 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin- 1 -yl)[ 1 ,2,4]triazolo[ 1 ,5-a]pyri- midine (known from DE-A 101 24 208) of the formula
Figure imgf000055_0002
Preferred mixing partners of group (23) are
(23-1) 2-butoxy-6-iodo-3-propylbenzopyran-4-one (known from WO 03/014103) of the formula
Figure imgf000055_0003
(23-2) 2-ethoxy-6-iodo-3-propylbenzopyran-4-one (known from WO 03/014103) of the formula
Figure imgf000055_0004
(23-3) 6-iodo-2-propoxy-3-propylbenzopyran-4-one (known from WO 03/014103) of the formula
Figure imgf000056_0001
(23-4) 2-but-2-ynyloxy-6-iodo-3-propylbenzopyran-4-one (known from WO 03/014103) of the formula
Figure imgf000056_0002
(23-5) 6-iodo-2-(l-methylbutoxy)-3-propylbenzopyran-4-one (known from WO 03/014103) of the formula
Figure imgf000056_0003
(23-6) 2-but-3-enyloxy-6-iodobenzopyran-4-one (known from WO 03/014103) of the formula
Figure imgf000056_0004
(23-7) 3-butyl-6-iodo-2-isopropoxybenzopyran-4-one (known from WO 03/014103) of the formula
Figure imgf000056_0005
Preferred mixing partners of group (24) are
(24-1) N-(3',4'-dichloro-5-fluoro-l,l'-biphenyl-2-yl)-3-(difluoromethyl)-l-methyl-lH-pyrazole-4- carboxamide (known from WO 03/070705) of the formula
Figure imgf000057_0001
(24-2) 3-(difluoromethyl)-N-{3'-fluoro-4'-[(£)-(methoxyimino)methyl]-l,lt-biphenyl-2-yl}-l- methyl-lH-pyrazole-4-carboxamide (known from WO 02/08197) of the formula
Figure imgf000057_0002
(24-3) 3-(trifluoromethyl)-N-{3'-fluoro-4'-[(£)-(methoxyimino)methyl]-l,l'-biphenyl-2-yl}-l- methyl- lH-pyrazole-4-carboxamide (known from WO 02/08197) of the formula
Figure imgf000057_0003
(24-4) N-(3',4'-dichloro-l,r-biphenyl-2-yl)-5-fluoro-l,3-dimethyl-lH-pyrazole-4-carboxamide (known from WO 00/14701) of the formula
Figure imgf000058_0001
(24-5) N-(4'-chloro-3 '-fluoro- 1 , 1 '-bipheny 1-2-y l)-2-methy l-4-(trifluoromethy I)- 1 ,3-thiazole-5- carboxamide (known from WO 03/066609) of the formula
Figure imgf000058_0002
(24-6) N-(4'-chloro-l,l'-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-l,3-thiazole-5-carboxamide (known from WO 03/066610) of the formula
Figure imgf000058_0003
(24-7) N-(4'-bromo-l ,1 '-bipheny 1-2-y l)-4-(difluoromethyl)-2-methy 1-1 ,3-thiazole-5-carboxamide (known from WO 03/066610) of the formula
Figure imgf000058_0004
(24-8) 4-(difluoromethyl)-2-methyl-N-[4'-(trifluoromethyl)- 1 , 1 '-biphenyl-2-yl] - 1 ,3 -thiazole-5 - carboxamide (known from WO 03/066610) of the formula
Figure imgf000059_0001
Compound (6-7), carpropamid, has three asymmetrically substituted carbon atoms. Accordingly, compound (6-7) can be present as a mixture of different isomers or else in the form of a single component. Particular preference is given to the compounds
(lS,3i?)-2,2-dichloro-N-[(l/?)-l-(4-chlorophenyl)ethyl]-l-ethyl-3-methylcyclopropanecarboxamide of the formula
Figure imgf000059_0002
(li?,35)-2,2-dichloro-N-[(li?)-l-(4-chlorophenyl)ethyl]-l-ethyl-3-methylcyclopropanecarboxamide of the formula
Figure imgf000059_0003
Particularly preferred mixing partners are the following active compounds:
(2-1) azoxystrobin
(2-2) fluoxastrobin
(2-3) (2£)-2-(2-{[6-(3-chloro-2-methylphenoxy)-5-fluoro-4-pyrimidinyl]oxy}phenyl)-2- (methoxyimino)-N-methylethanamide (2-4) trifloxystrobin
(2-5) (2£)-2-(methoxyimino)-N-methyl-2-(2- { [( {( IE)- 1 -[3-(trifluoromethyl)- phenyl]ethyliden}amino)oxy]methyl}phenyl)ethanamide
(2-6) (2jE>2-(methoxyimino)-N-methyl-2- {2-[(£)-( { 1 -[3-(trifluoromethyl)phenyl]- ethoxy } imino)methyl]phenyl } ethanami de
(2-8) 5-methoxy-2-methyl-4-(2-{[({(l£)-l-[3-(trifluoromethyl)phenyl]ethyliden}- amino)oxy]methyl}phenyl)-2,4-dihydro-3H-l,2,4-triazol-3-one
(2-11) picoxystrobin
(2-9) kresoxim-methyl
(2-10) dimoxystrobin
(2-12) pyraclostrobin
(2-13) metominostrobin
(3-3) propiconazole
(3-4) difenoconazole
(3-6) cyproconazole
(3-7) hexaconazole
(3-8) penconazole
(3-9) myclobutanil
(3-10) tetraconazole
(3-12) epoxiconazole
(3-13) flusilazole (3-15) prothioconazole
(3-16) fenbuconazole
(3-17) tebuconazole
(3-19) metconazole (3-21) bitertanol
(3-22) triadimenol
(3-23) triadimefon
(3-24) fluquinconazole
(4-1) dichlofluanid (4-2) tolylfluanid
(5-1) iprovalicarb
(5-3) benthiavalicarb
(6-2) boscalid
(6-5) ethaboxam (6-6) fenhexamid
(6-7) carpropamid
(6-8) 2-chloro-4-[(2-fluoro-2-methylpropanoyl)amino]-Nv/V-dimethylbenzamide
(6-9) picobenzamid
(6-10) zoxamide (6-11) 3,4-dichloro-Ν-(2-cyanophenyl)isothiazole-5-carboxamide (6-14) penthiopyrad
(6-16) N-fZ^l^-dimethylbuty^pheny^-l-methyM-^fluoromethyO-lH-pyrrole-S-carboxamide
(6-17) Ν-{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}-2-(trifluoromethyl)benzamide
(6a-2) N-[2-(l,3-dimethylbutyl)phenyl]-5-fluoro-l,3-dimethyl-lH-pyrazole-4-carboxamide (pyflufen)
(6b-2) Ν-(2-[ 1 , 1 '-bicyclopropyl] -2-ylphenyl)-3 -(difluoromethyl)- 1 -methyl- 1 Η-pyrazole-4- carboxamide
(7-1) mancozeb
(7-2) maneb
(7-4) propineb
(7-5) thiram
(7-6) zineb
(8-1) benalaxyl
(8-2) furalaxyl
(8-3) metalaxyl
(8-4) metalaxyl-M
(8-5) benalaxyl-M
(9-1) cyprodinil
(9-2) mepanipyrim
(9-3) pyrimethanil (10-1) 6-chloro-5-[(3,5-dimethylisoxazol-4-yl)sulphonyl]-2,2-difluoro-5H-[l,3]dioxolo[4,5-f]- benzimidazole
(10-3) carbendazim
(11-1) diethofencarb (11-2) propamocarb
(11-3) propamocarb-hydrochloride
(11-4) propamocarb-fosetyl
(12-2) captan
(12-3) folpet (12-4) iprodione
(12-5) procymidone
(13-1) dodine
(13-2) guazatine
(13-3) iminoctadine triacetate (14-1) cyazofamid
(14-2) prochloraz
(14-3) triazoxide
(15-5) dimethomorph
(15-4) fenpropimoφh (16-2) fludioxonil (17-1) fosetyl-Al
(17-2) phosphonic acid
(19-1) acibenzolar-S-methyl
(19-2) chlorothalonil
(19-3) cymoxanil
(19-5) famoxadone
(19-6) fluazinam
(19-9) oxadixyl
(19-10) spiroxamine
(19-7) copper oxychloride
(19-13) fenamidone
( 19-22) 2-(4-chlorophenyl)-N- {2-[3 -methoxy-4-(prop-2-yn-l -yloxy)phenyl]ethyl} -2-(prop-2-yn- 1 - yloxy)acetamide
(20-1) pencycuron
(20-2) thiophanate-methyl
(22-1) 5-chloro-N-[f75>2,2,2-trifluoro-l-methylethyl]-6-(2,4,6-trifluorophenyl)[l,2,4]- triazolof 1 ,5-a]pyrimidine-7-amine
(22-2) S-chloro-N-tfy^-l^-dimethylpropyll-o^^.o-trifluorophenyOtl^^Jtriazolotl^-a]- pyrimidine-7-amine
(22-4) 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-l-yl)[l,2,4]triazolo[l,5-a]pyri- midine (23-1) 2-butoxy-6-iodo-3-propylbenzopyran-4-one
(23-2) 2-ethoxy-6-iodo-3-propylbenzopyran-4-one
(23-3) 6-iodo-2-propoxy-3-propylbenzopyran-4-one
(24-1) N-(3',41-dichloro-5-fluoro-l,l'-biphenyl-2-yl)-3-(difluoromethyl)-l-methyl-lH-pyrazole-4- carboxamide
(24-3) 3-(trifluoromethyl)-N-{3'-fluoro-4l-[(£r)-(methoxyimino)methyl]-l,ll-biphenyl-2-yl}-l- methyl- 1 H-pyrazole-4-carboxamide
(24-7) N-(4'-bromo-l,r-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-l,3-thiazole-5-carboxamide.
Very particularly preferred mixing partners are the following active compounds:
(2-2) fluoxastrobin
(2-4) trifloxystrobin
(2-3) (2£0-2-(2-{[6-(3-chloro-2-methylphenoxy)-5-fluoro-4-pyrimidinyl]oxy}phenyl)-2- (methoxyimino)-N-methylethanamide
(3-15) prothioconazole
(3-17) tebuconazole
(3-21) bitertanol
(3-22) triadimenol
(3-24) fluquinconazole
(4-1) dichlofluanid
(4-2) tolylfluanid
(5-1) iprovalicarb (6-6) fenhexamid
(6-9) picobenzamid
(6-7) carpropamid
(6-14) penthiopyrad
(6-17) N-{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}-2-(trifluoromethyl)benzamide
(6a-2) N-[2-(l,3-dimethylbutyl)phenyl]-5-fluoro-l,3-dimethyl-lH-pyrazole-4-carboxamide (pyflufen)
(6b-2) Ν-(2-[l,r-bicyclopropyl]-2-ylphenyl)-3-(difluoromethyl)-l-methyl-lΗ-pyrazole-4- carboxamide
(7-4) propineb
(8-4) metalaxyl-M
(8-5) benalaxyl-M
(9-3) pyrimethanil
(10-3) carbendazim
(11-4) propamocarb-fosetyl
(12-4) iprodione
(14-2) prochloraz
(14-3) triazoxide
(16-2) fludioxonil
(19-10) spiroxamine ( 19-22) 2-(4-chlorophenyl)-N- {2-[3-methoxy-4-(prop-2-yn- 1 -yloxy)phenyl]ethyl } -2-(prop-2-yn- 1 - yloxy)acetamide
(22-4) 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-l -yl)[ 1 ,2,4]triazolo[ 1 ,5-a]pyri- midine
(24-1) N-(3',4'-dichloro-5-fluoro-l,r-biphenyl-2-yl)-3-(difluoromethyl)-l-methyl-lH-pyrazole-4- carboxamide.
Preferred active compound combinations comprising two groups of active compounds and in each case at least genistein of the formula (I) and at least one active compound of the given group (2) to (24) are described below. These combinations are the active compound combinations A to U.
In addition to genistein of the formula (I), the active compound combinations A also comprise a strobilurin of the formula (II) (group 2)
Figure imgf000067_0001
in which A1, L and R11 are as defined above.
Preferred are active compound combinations A in which the strobilurin of the formula (JL) (group 2) is selected from the list below:
(2-1) azoxystrobin
(2-2) fluoxastrobin
(2-3) (2£)-2-(2-{[6-(3-chloro-2-methylphenoxy)-5-fluoro-4-pyrimidinyl]oxy}phenyl)-2- (methoxyimino)-N-methylethanamide
(2-4) trifloxystrobin
(2-5) (2j?)-2-(methoxyimino)-N-methyl-2-(2-{[({(l^)-l-[3-(trifluoromethyl)phenyl]- ethyliden}amino)oxy]methyl}phenyl)ethanamide (2-6) (2^)-2-(methoxyimino)-N-methyl-2-{2-[(£)-({l-[3-(trifluoromethyl)phenyl]ethoxy}- imino)methyl]phenyl } ethanamide
(2-7) orysastrobin
(2-8) 5-methoxy-2-methyl-4-(2- {[( {( IE)-I -[3-(trifluoromethyl)phenyl]ethyliden} - amino)oxy]methyl}phenyl)-2,4-dihydro-3H-l ,2,4-triazol-3-one
(2-9) kresoxim-methyl
(2-10) dimoxystrobin
(2-11) picoxystrobin
(2-12) pyraclostrobin
(2-13) metominostrobin
Particularly preferred are active compound combinations A in which the strobilurin of the formula (II) (group 2) is selected from the list below:
(2-1) azoxystrobin
(2-2) fluoxastrobin
(2-3) (2£)-2-(2-{[6-(3-chloro-2-methylphenoxy)-5-fluoro-4-pyrimidinyl]oxy}phenyl)-2- (methoxyimino)-N-methylethanamide
(2-4) trifloxystrobin
(2-12) pyraclostrobin
(2-9) kresoxim-methyl
(2-10) dimoxystrobin
(2-11) picoxystrobin (2-13) metominostrobin
Emphasis is given to the active compound combinations A listed in Table 1 below:
Table 1: Active compound combinations A
Figure imgf000069_0001
In addition to genistein of the formula (I), the active compound combinations B also comprise a triazole of the formula (HT) (group 3)
Figure imgf000070_0001
in which Q, m, R14, R15, A4, A5, R16 and R17 are as defined above.
Preference is given to active compound combinations B in which the triazole of the formula (HI) (group 3) is selected from the list below:
(3-1) azaconazole
(3-2) etaconazole
(3-3) propiconazole
(3-4) difenoconazole
(3-5) bromuconazole
(3-6) cyproconazole
(3-7) hexaconazole
(3-8) penconazole
(3-9) myclobutanil
(3-10) tetraconazole
(3-11) flutriafol
(3-12) epoxiconazole (3-13) flusilazole
(3-14) simeconazole
(3-15) prothioconazole
(3-16) fenbuconazole
(3-17) tebuconazole
(3-18) ipconazole
(3-19) metconazole
(3-20) triticonazole
(3-21) bitertanol
(3-22) triadimenol
(3-23) triadimefon
(3-24) fluquinconazole
(3-25) quinconazole
Particular preference is given to active compound combinations B in which the triazole of the formula (EI) (group 3) is selected from the list below:
(3-3) propiconazole
(3-6) cyproconazole
(3-15) prothioconazole
(3-17) tebuconazole
(3-21) bitertanol (3-4) difenoconazole (3-7) hexaconazole (3-19) metconazole (3-22) triadimenol (3-24) fluquinconazole
Emphasis is given to the active compound combinations B listed in Table 2 below: Table 2: Active compound combinations B
Figure imgf000072_0001
In addition to genistein of the formula (I), the active compound combinations C also comprise a sulphenamide of the formula (IV) (group 4)
Figure imgf000073_0001
in which R is as defined above.
Preference is given to active compound combinations C in which the sulphenamide of the formula (IV) (group 4) is selected from the list below:
(4-1) dichlofluanid
(4-2) tolylfluanid
Emphasis is given to the active compound combinations C listed in Table 3 below:
Table 3: Active compound combinations C
Figure imgf000073_0002
In addition to genistein of the formula (I), the active compound combinations D also comprise a valinamide (group 5) selected from
(5-1) iprovalicarb
(5-2) N1-[2-(4-{[3-(4-chlorophenyl)-2-propynyl]oxy}-3-methoxyphenyl)ethyl]-N2-(methyl- sulphonyl)-D-valinamide
(5-3) benthiavalicarb Preference is given to active compound combinations D in which the valinamide (group 5) is selected from the list below:
(5-1) iprovalicarb
(5-3) benthiavalicarb
Emphasis is given to the active compound combinations D listed in Table 4 below:
Table 4: Active compound combinations D
Figure imgf000074_0002
In addition to genistein of the formula (I), the active compound combinations E also comprise a carboxamide of the formula (V) (group 6)
Figure imgf000074_0001
in which X, Y and Z are as defined above.
Preference is given to active compound combinations E in which the carboxamide of the formula (V) (group 6) is selected from the list below:
(6- 1 ) 2-chloro-N-( 1 , 1 ,3 -trimethylindan-4-yl)nicotinarnide
(6-2) boscalid
(6-3) furametpyr
(6-4) N-(3 -p-tolylthiophen-2-yl)- 1 -methyl-3 -trifluoromethyl- 1 H-pyrazole-4-carboxamide
(6-5) ethaboxam (6-6) fenhexamid
(6-7) carpropamid
(6-8) 2-chloro-4-(2-fluoro-2-methylpropionylamino)-N,N-dimethylbenzamide
(6-9) picobenzamid
(6-10) zoxamide
(6-11) 3 ,4-dichloro-N-(2-cyanophenyl)isothiazole-5 -carboxamide
(6-12) carboxin
(6-13) tiadinil
(6-14) penthiopyrad
(6-15) silthiofam
(6- 16) N-[2-( 1 ,3-dimethylbutyl)phenyl]- 1 -methyl-4-(trifluoromethyl)- lH-pyrrole-3 -carboxamide
(6-17) Ν-{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}-2-(trifluoromethyl)benzamide
(6a-2) N-[2-(l,3-dimethylbutyl)phenyl]-5-fluoro-l,3-dimethyl-lH-pyrazole-4-carboxaniide (pyflufen)
(6b-2) Ν-(2-[ 1 , 1 '-bicyclopropyl]-2-ylphenyl)-3-(difluoromethyl)- 1 -methyl- 1 Η-pyrazole-4- carboxamide
Particular preference is given to active compound combinations E in which the carboxamide of the formula (V) (group 6) is selected from the list below:
(6-2) boscalid
(6-5) ethaboxam
(6-6) fenhexamid (6-7) carpropamid
(6-8) 2-chloro-4-(2-fluoro-2-methyl-propionylamino)-N,N-dimethylbenzamide
(6-9) picobenzamid
(6-10) zoxamide
(6-11) 3,4-dichloro-N-(2-cyanophenyl)isothiazole-5-carboxamide
(6-14) penthiopyrad
(6-16) N-[2-(l,3-dimethylbutyl)phenyl]-l-methyl-4-(trifluoromethyl)-lH-pyrrole-3-carboxamide
Very particular preference is given to active compound combinations E in which the carboxamide of the formula (V) (group 6) is selected from the list below:
(6-2) boscalid
(6-6) fenhexamid
(6-7) carpropamid
(6-9) picobenzamid
(6-14) penthiopyrad
(6-17) Ν- {2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl} -2-(trifluoromethyl)benzamide
(6a-2) N-[2-(l ,3-dimethylbutyl)phenyl]-5-fluoro-l ,3-dirnethyl-lH-pyrazole-4-carboxamide (pyflufen)
(6b-2) Ν-(2-[ 1 , 1 '-bicyclopropyl] -2-ylphenyl)-3 -(difluoromethyl)- 1 -methyl- 1 Η-pyrazole-4- carboxamide
Emphasis is given to the active compound combinations E listed in Table 5 below: Table 5: Active compound combinations E
Figure imgf000077_0001
In addition to genistein of the formula (I), the active compound combinations F also comprise a dithiocarbamate (group 7) selected from
(7-1) mancozeb
(7-2) maneb
(7-3) metiram
(7^) propineb
(7-5) thiram
(7-6) zineb
(7-7) ziram
Preference is given to active compound combinations F in which the dithiocarbamate (group 7) is selected from the list below:
(7-1) mancozeb
(7-2) maneb (7-4) propineb
(7-5) thiram
(7-6) zineb
Particular preference is given to active compound combinations F in which the dithiocarbamate (group 7) is selected from the list below:
(7-1) mancozeb
(7-4) propineb
Emphasis is given to the active compound combinations F listed in Table 6 below:
Table 6: Active compound combinations F
Figure imgf000078_0002
In addition to genistein of the formula (I), the active compound combinations G also comprise an acylalanine of the formula (VI) (group 8)
Figure imgf000078_0001
in which * and R are as defined above.
Preference is given to active compound combinations G in which the acylalanine of the formula (VI) (group 8) is selected from the list below:
(8-1) benalaxyl (8-2) furalaxyl
(8-3) metalaxyl
(8-4) metalaxyl-M
(8-5) benalaxyl-M
Particular preference is given to active compound combinations G in which the acylalanine of the formula (VT) (group 8) is selected from the list below:
(8-3) metalaxyl
(8-4) metalaxyl-M
(8-5) benalaxyl-M
Emphasis is given to the active compound combinations G listed in Table 7 below:
Table 7: Active compound combinations G
Figure imgf000079_0001
In addition to genistein of the formula (I), the active compound combinations H also comprise an anilinopyrimidine (group 9) selected from
(9-1) cyprodinil
(9-2) mepanipyrim
(9-3) pyrimethanil Emphasis is given to the active compound combinations H listed in Table 8 below:
Table 8: Active compound combinations H
Figure imgf000080_0002
In addition to genistein of the formula (I), the active compound combinations I also comprise a benzimidazole of the formula (VIQ) (group 10)
Figure imgf000080_0001
in which R25, R26, R27 and R28 are as defined above.
Preference is given to active compound combinations I in which the benzimidazole of the formula (Vπi) (group 10) is selected from the list below:
(10-1) 6-chloro-5-[(3,5-dimethylisoxazol-4-yl)sulphonyl]-2,2-difluoro-5H-[l,3]dioxolo[4,5-f]- benzimidazole
(10-2) benomyl
(10-3) carbendazim
(10-4) chlorfenazole
(10-5) fuberidazole
(10-6) thiabendazole Particular preference is given to active compound combinations I in which the benzimidazole of the formula (Vm) (group 10) is:
(10-3) carbendazim
Emphasis is given to the active compound combinations I listed in Table 9 below:
Table 9: Active compound combinations I
Figure imgf000081_0002
In addition to genistein of the formula (I), the active compound combinations J also comprise a carbamate (group 11) of the formula (IX)
Figure imgf000081_0001
in which R29 and R30 are as defined above.
Preference is given to active compound combinations J in which the carbamate (group 11) is selected from the list below:
(11-1) diethofencarb
(11-2) propamocarb
(11-3) propamocarb-hydrochloride
(11-4) propamocarb-fosetyl
Emphasis is given to the active compound combinations J listed in Table 10 below: Table 10: Active compound combinations J
Figure imgf000082_0001
In addition to genistein of the formula (I), the active compound combinations K also comprise a dicarboximide (group 12) selected from
(12-1) captafol
(12-2) captan
(12-3) folpet
(12-4) iprodione
(12-5) procymidone
(12-6) vinclozolin
Preference is given to active compound combinations K in which the dicarboximide (group 12) is selected from the list below:
(12-2) captan
(12-3) folpet
(12-4) iprodione Emphasis is given to the active compound combinations K listed in Table 11 below:
Table 11 : Active compound combinations K
Figure imgf000083_0001
In addition to genistein of the formula (I), the active compound combinations L also comprise a guanidine (group 13) selected from
(13-1) dodine
(13-2) guazatine
(13-3) iminoctadine triacetate
(13-4) iminoctadine tris(albesilate)
Preference is given to active compound combinations L in which the guanidine (group 13) is selected from the list below:
(13-1) dodine
(13-2) guazatine Emphasis is given to the active compound combinations L listed in Table 12 below:
Table 12: Active compound combinations L
Figure imgf000084_0001
In addition to genistein of the formula (I), the active compound combinations M also comprise an imidazole (group 14) selected from
(14-1) cyazofamid
(14-2) prochloraz
(14-3) triazoxide
(14-4) pefurazoate
Preference is given to active compound combinations M in which the imidazole (group 14) is selected from the list below:
(14-2) prochloraz
(14-3) triazoxide
Emphasis is given to the active compound combinations M listed in Table 13 below:
Table 13: Active compound combinations M
Figure imgf000085_0002
In addition to genistein of the formula (I), the active compound combinations N also comprise a morpholine (group 15) of the formula (X)
Figure imgf000085_0001
in which R , R and R are as defined above.
Preference is given to active compound combinations N in which the morpholine (group 15) of the formula (X) is selected from the list below:
(15-1) aldimorph
(15-2) tridemorph
(15-3) dodemorph
(15-4) fenpropimorph
(15-5) dimethomorph
Particular preference is given to active compound combinations N in which the morpholine (group 15) of the formula (X) is selected from the list below:
(15-4) fenpropimorph (15-5) dimethomorph
Emphasis is given to the active compound combinations N listed in Table 14 below:
Table 14: Active compound combinations N
Figure imgf000086_0002
In addition to genistein of the formula (I), the active compound combinations O also comprise a pyrrole (group 16) of the formula (XI)
Figure imgf000086_0001
in which R34, R35 and R36 are as defined above.
Preference is given to active compound combinations O in which the pyrrole (group 16) of the formula (XI) is selected from the list below:
(16-1) fenpiclonil
(16-2) fludioxonil
(16-3) pyrrolnitrin
Particular preference is given to active compound combinations O in which the pyrrole (group 16) of the formula (XI) is selected from the list below:
(16-2) fludioxonil Emphasis is given to the active compound combinations O listed in Table 15 below:
Table 15: Active compound combinations O
Figure imgf000087_0001
In addition to genistein of the formula (I), the active compound combinations P also comprise a phosphonate (group 17) selected from
(17-1) fosetyl-Al
(17-2) phosphonic acid
Emphasis is given to the active compound combinations P listed in Table 16 below:
Table 16: Active compound combinations P
Figure imgf000087_0002
In addition to genistein of the formula (I), the active compound combinations Q also comprise a fungicide (group 19) selected from
(19-1) acibenzolar-S-methyl
(19-2) chlorothalonil
(19-3) cymoxanil
(19-4) edifenphos
(19-5) famoxadone (19-6) fluazinam
(19-7) copper oxychloride
(19-8) copper hydroxide
(19-9) oxadixyl
(19-10) spiroxamine
(19-l l) dithianon
(19-12) metrafenone
(19-13) fenamidone
(19-14) 2,3-dibutyl-6-chlorothieno[2,3-d]pyrimidin-4(3H)-one
(19-15) probenazole
(19-16) isoprothiolane
(19-17) kasugamycin
(19-18) phthalide
(19-19) ferimzone
(19-20) tricyclazole
( 19-21 ) N-( {4-[(cyclopropylamino)carbonyl]phenyl} sulphonyl)-2-methoxybenzamide
( 19-22) 2-(4-chlorophenyl)-N- {2-[3-methoxy-4-(prop-2-yn- 1 -yloxy)phenyl]ethyl} -2-(prop-2-yn- 1 - yloxy)acetamide
Preference is given to active compound combinations Q in which the fungicide (group 19) is selected from the list below: (19-1) acibenzolar-S-methyl
(19-2) chlorothalonil
(19-3) cymoxanil
(19-5) famoxadone
(19-6) fluazinam
(19-7) copper oxychloride
(19-9) oxadixyl
(19-10) spiroxamine
(19-13) fenamidone
(19-21 ) N-( {4-[(cyclopropylamino)carbonyl]phenyl} sulphonyl)-2-methoxybenzamide
(19-22) 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-l-yloxy)phenyl]ethyl}-2-(prop-2-yn-l- yloxy)acetamide
Particular preference is given to active compound combinations Q in which the fungicide (group 19) is selected from the following list:
(19-2) chlorothalonil
(19-7) copper oxychloride
(19-10) spiroxamine
(19-21) N-( {4-[(cyclopropylamino)carbonyl]phenyl} sulphonyl)-2-methoxybenzamide
( 19-22) 2-(4-chlorophenyl)-N- {2-[3-methoxy-4-(prop-2-yn- 1 -yloxy)phenyl]ethyl} -2-(prop-2-yn- 1 - yloxy)acetamide Emphasis is given to the active compound combinations Q listed in Table 17 below:
Table 17: Active compound combinations Q
Figure imgf000090_0001
In addition to genistein of the formula (T), the active compound combinations R also comprise a (thio)urea derivative (group 20) selected from
(20-1) pencycuron
(20-2) thiophanate-methyl
(20-3) thiophanate-ethyl
Preference is given to active compound combinations R in which the (thio)urea derivative (group 20) is selected from the list below:
(20-1) pencycuron
(20-2) thiophanate-methyl Emphasis is given to the active compound combinations R listed in Table 18 below:
Table 18: Active compound combinations R
Figure imgf000091_0002
In addition to genistein of the formula (I),, the active compound combinations S also comprise a triazolopyrimidine (group 22) of the formula (XIV)
Figure imgf000091_0001
in which R40, R41, R42, R43, R44, R45, R46 and R47 are as defined above.
Preference is given to active compound combinations S in which the triazolopyrimidine (group 22) of the formula (XIV) is selected from the list below:
(22-1) 5-chloro-N-[^/5>2,2,2-trifluoro-l-methylethyl]-6-(2,4,6-trifluorophenyl)[l,2,4]triazolo- [l,5-a]pyrimidine-7-amine
(22-2) 5-chloro-N-[(7i?>l,2-dimethylpropyl]-6-(2,4,6-trifluorophenyl)[l,2,4]triazolo[l,5-a]- pyrimidine-7 -amine
(22-3) 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4-methylpiperidin-l -yl)[ 1 ,2,4]triazolo[ 1 ,5-a]- pyrimidine
(22-4) 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-l-yl)[l,2,4]triazolo[l,5-a]pyri- midine
Particular preference is given to active compound combinations S in which the triazolopyrimidine (group 22) of the formula (XIV) is selected from the list below: (22-1) S-chloro-N-tfy^^^^-trifluoro-l-methylethy^-o^^.o-trifluorophenyOtl^.^triazolo- [ 1 ,5 -a]pyrimidine-7 -amine
(22-2) 5-ch\oτo-N-[(lR)- 1 ,2-dimethylpropyl]-6-(2,4,6-trifluorophenyl)[ 1 ,2,4]triazolo[ 1 ,5-a]- pyrimidine-7-amine
(22-4) 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin- 1 -yl)[ 1 ,2,4]triazolo[l ,5-a]pyri- midine
Emphasis is given to the active compound combinations S listed in Table 19 below:
Table 19: Active compound combinations S
Figure imgf000092_0002
In addition to genistein of the formula (I), the active compound combinations T also comprise an iodochromone (group 23) of the formula (XV)
Figure imgf000092_0001
in which R and R are as defined above.
Preference is given to active compound combinations T in which the iodochromone (group 23) of the formula (XV) is selected from the list below:
(23-1) 2-butoxy-6-iodo-3-propylbenzopyran-4-one (23 -2) 2-ethoxy-6-iodo-3 -propylbenzopyran-4-one
(23-3) 6-iodo-2-propoxy-3-propylbenzopyran-4-one
(23-4) 2-but-2-ynyloxy-6-iodo-3-propylbenzopyran-4-one
(23-5) 6-iodo-2-(l-methylbutoxy)-3-propylbenzopyran-4-one
(23-6) 2-but-3-enyloxy-6-iodobenzopyran-4-one
(23-7) 3 -butyl-6-iodo-2-isopropoxybenzopyran-4-one
Particular preference is given to active compound combinations T in which the iodochromone (group 23) of the formula (XV) is selected from the list below:
(23-1) 2-butoxy-6-iodo-3-propylbenzopyran-4-one
(23-2) 2-ethoxy-6-iodo-3-propylbenzopyran-4-one
Emphasis is given to the active compound combinations T listed in Table 20 below:
Table 20: Active compound combinations T
Figure imgf000093_0001
In addition to genistein of the formula (I), the active compound combinations U also comprise a biphenylcarboxamide (group 24) of the formula (XVI)
Figure imgf000094_0001
in which R50, R51, R52 and Het are as defined above.
Preference is given to active compound combinations U in which the biphenylcarboxamide (group 24) of the formula (XVI) is selected from the list below:
(24-1) N-(3',4'-dichloro-5-fluoro-l,l'-biphenyl-2-yl)-3-(difluoromethyl)-l-methyl-lH-pyrazole-4- carboxamide
(24-2) 3-(difluoromethyl)-N-{3'-fluoro-4'-[(£)-(methoxyimino)methyl]-l , 1 '-biphenyl-2-yl}-l - methyl- lH-pyrazole-4-carboxamide
(24-3) 3-(trifluoromethyl)-N-{3'-fluoro-4l-[(£)-(methoxyimino)methyl]-l,l'-biphenyl-2-yl}-l- methyl- lH-pyrazole-4-carboxamide
(24-4) ^(S'^'-dichloro-l.r-biphenyl^-yO-S-fluoro-l^-dimethyl-lH-pyrazole^-carboxamide
(24-5) N-(4'-chloro-3l-fluoro-l,l'-biphenyl-2-yl)-2-methyl-4-(trifluoromethyl)-l,3-thiazole-5- carboxamide
(24-6) N-(4'-chloro-l,r-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-l,3-thiazole-5-carboxamide
(24-7) N-(4'-bromo- 1 , 1 '-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-l ,3-thiazole-5-carboxamide
(24-8) 4-(difluoromethyl)-2-methyl-N-[4'-(trifluoromethyl)-l,l'-biphenyl-2-yl]-l,3-thiazole-5- carboxamide.
Particular preference is given to active compound combinations U in which the biphenylcarboxamide (group 24) of the formula (XVI) is selected from the list below: (24-1) N-(3t,41-dichloro-5-fluoro-l,l'-biphenyl-2-yl)-3-(difluoromethyl)-l-methyl-lH-pyrazole-4- carboxamide
(24-3) S^trifluoromethyO-N-IS'-fluoro^'-f^^methoxyimino^ethylj-l.l'-biphenyl^-yl}-!- methyl- lH-pyrazole-4-carboxamide
(24-7) N-(4'-bromo- 1 , 1 '-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl- 1 ,3 -thiazole-5 -carboxamide
Emphasis is given to the active compound combinations U listed in Table 21 below:
Table 21: Active compound combinations U
Figure imgf000095_0001
In addition to genistein of the formula (I), the active compound combinations according to the invention comprise at least one active compound from the compounds of groups (2) to (24). In addition, they may also comprise further fungicidally active additives.
If the active compounds in the active compound combinations according to the invention are present in certain weight ratios, the synergistic effect is particularly pronounced. However, the weight ratios of the active compounds in the active compound combinations can be varied within a relatively wide range. In general, the active compound combinations according to the invention comprise active genistein and a mixing partner from one of the groups (2) to (24) in the mixing ratios listed in an exemplary manner in Table 22 below.
The mixing ratios are based on ratios by weight. The ratio is to be understood as active compound genistein of the formula (T): mixing partner. Table 22: Mixing ratios
Figure imgf000096_0001
Table 22: Mixing ratios
Mixing partner Preferred mixing ratio Particularly preferred mixing ratio
(19-1): acibenzolar-S-methyl 50 : 1 to 1 :50 20:1 to 1 :20
(19-2): chlorothalonil 1 : 1 to 1 : 150 1 : 1 to 1 : 100
(19-3): cymoxanil 10 : 1 to 1 :50 5:1 to 1 :20
(19-4): edifenphos 10 : 1 to 1 :50 5:1 to i :20
(19-5): famoxadone 50 : 1 to 1 :50 10:1 to 1 :20
(19-6): fluazinam 50 : 1 to 1 :50 10:1 to 1 :20
(19-7): copper oxychloride 1: 1 to 1 : 150 1 :5 to 1 :100
(19-8): copper hydroxide 1 : 1 to 1 : 150 1 :5 to 1 : 100
(19-9): oxadixyl 10 : 1 to 1 : 150 5: 1 to 1 : 100
(19-10): spiroxamine 50 : 1 to 1 :50 10: 1 to 1 :20
(19-11) dithianon 50 : 1 to 1 :50 10: 1 to 1 :20
(19-12) metrafenone 50 : 1 to 1 :50 10: 1 to 1 :20
(19-13) fenamidone 50 : 1 to 1 :50 10: 1 to 1:20
(19-14): 2 ,3 -dibutyl-6-chlorothieno-
50 : 1 to 1 :50 10: 1 to 1 :20 [2 ,3 -d]pyrimidin-4(3H)one
(19-15): probenazole 10 : 1 to 1 : 150 5: 1 to 1 : 100
(19-16): isoprothiolane 10 : 1 to 1 : 150 5: 1 to 1 : 100
(19-17): kasugamycin 50 : 1 to 1 :50 10: 1 to 1 :20
(19-18): phthalide 10 : 1 to 1 : 150 5: 1 to 1 : 100
(19-19): ferimzone 50 : 1 to 1 :50 10: 1 to 1:20
(19-20): tricyclazole 50 : 1 to 1 :50 10: 1 to 1 :20 Table 22: Mixing ratios
Figure imgf000098_0001
Further preferred mixing ratios are:
Table 22a:
Mixing partner Preferred mixing ratio Particularly preferred mixing ratio
Group (2): strobilurins 10: 1 to 1 : 1014 1 : 1 to l:109
Group (3): triazoles except for (3-15) 10:1 to 1 : 1014 1 : 1 to l:109
(3-15): prothioconazole 10: 1 to 1 : 1014 1 : 1 to l:109
Group (4): sulphenamides 10: 1 to 1 : 1014 1 : 1 to l:109
Group (5): valinamides 10: 1 to 1 : 1014 1 : 1 to l:109 Table 22a:
Mixing partner Preferred mixing ratio Particularly preferred mixing ratio
Group (6): carboxamides 10 : 1 to 1 : 1014 1 : 1 to l: 109
Group (7): dithiocarbamates 10 : 1 to 1 : 1014 1 :1 to l : 109
Group (8): acylalanines 10 : 1 to 1 : 1014 1 : 1 to l : 109
Group (9): anilinopyrimidines 10 : 1 to 1 : iθ!4 i : i to 1 : 109
Group (10): benzimidazoles 10 : 1 to 1 : 1014 1 : 1 to l : 109
Group (11): carbamates except for (11-1) 10 : 1 to 1 : 1014 1 : 1 to l : 109
(11-1): diethofencarb 10 : 1 to 1 : 1014 1 : 1 to l :109
Group (12): (12-l)/(12-2)/(12-3) 10 : 1 to 1 : 1014 1 :5 to l :109
Group (12): (12^)/(12-5)/(12-6) 10 : 1 to 1 : 1014 1 : 1 to l :109
Group (13): guanidines 10 : 1 to 1 : 1014 1 : 1 to l : 109
Group (14): imidazoles 10 : 1 to 1 : 1014 1 : 1 to l : 109
Group (15): morpholines 10 : 1 to 1 : 1014 1 : 1 to l :109
Group (16): pyrroles 10 : 1 to 1 : 1014 1 :1 to l :109
Group (17): phosphonates 10 : 1 to 1 : 1014 1 : 1 to l : 109
Group (18): phenylethanamides 10 : 1 to 1 : 1014 1 : 1 to l :109
(19-1): acibenzolar-S-methyl 10 : 1 to 1 : 1014 1 : 1 to l : 109
(19-2): chlorothalonil 10 : 1 to 1 : 1014 1 : 1 to l : 109
(19-3): cymoxanil 10 : 1 to 1 : 1014 1: 1 to l :109
(19-4): edifenphos 10 : 1 to 1 : 1014 1 : 1 to l : 109
(19-5): famoxadone 10 : 1 to 1 : 1014 1 : 1 to l : 109 Table 22a:
Mixing partner Preferred mixing ratio Particularly preferred mixing ratio
(19-6): fluazinam 10: 1 to 1 : 1014 1 : 1 to l:109
(19-7): copper oxychloride 10: 1 to 1 : 1014 1 :5 to l:109
(19-8): copper hydroxide 10:1 to 1 : 1014 1 :5 to l:109
(19-9): oxadixyi iυ : 1 to 1 : 10!4 1 : i to 1 : 10"
(19-10): spiroxamine 10:1 to 1 : 1014 1 : 1 to l:109
(19-11) dithianon 10: 1 to 1 : 1014 1 : 1 to l:109
(19-12) metrafenone 10: 1 to 1 : 1014 1 : 1 to l:109
(19-13) fenamidone 10: 1 to 1 : 1014 1 : 1 to l:109
(19-14): 2,3-dibutyl-6-chlorothieno-
10: 1 to 1 : 1014 1 : 1 to l:109 [2,3-d]pyrimidin-4(3H)one
(19-15): probenazole 10: 1 to 1 : 1014 1 : 1 to 1 : 109
(19-16): isoprothiolane 10: 1 to 1 : 1014 1 : 1 to l:109
(19-17): kasugamycin 10: 1 to 1 : 1014 1 : 1 to l:109
(19-18): phthalide 10:1 to 1 : 1014 1 : 1 to l:109
(19-19): ferimzone 10: 1 to 1 : 1014 1 : 1 to l:109
(19-20): tricyclazole 10:1 to 1 : 1014 1 : 1 to l:109
(19-21): N-( {4-[(cyclopropylamino)- carbonyljphenyl} sulphonyl)-2- 10: 1 to 1 : 1014 1 : 1 to l:109 methoxybenzamide Table 22a:
Figure imgf000101_0001
In each case, the mixing ratio is to be chosen such that a synergistic mixture is obtained. The mixing ratios between the compound of the formula (I) and a compound of one of the groups (2) to (24) may also vary between the individual compounds of a group.
The active compound combinations according to the invention have very good fungicidal properties and are suitable for controlling phytopathogenic fungi, such as Plasmodiophoromycetes, Oomycetes, Chytridiomycetes, Zygomycetes, Ascomycetes, Basidiomycetes, Deuteromycetes, etc.
The active compound combinations according to the invention are particularly suitable for controlling seed and soil-borne pathogens.
Some pathogens causing fungal diseases which come under the generic names listed above may be mentioned by way of example, but not by way of limitation:
Powdery Mildew Diseases such as
Blumeria diseases caused for example by Blumeria graminis
Podosphaera diseases caused for example by Podosphaera leucotricha Sphaerotheca diseases caused for example by Sphaerotheca fuliginea
Uncinula diseases caused for example by Uncinula necator
Rust Diseases such as
Gymnosporangium diseases caused for example by Gymnosporangium sabinae
Hemileia diseases caused for example by Hemileia vastatrix
Phakopsora diseases caused for example by Phakopsora pachyrhizi and Phakopsora meibomiae
Puccinia diseases caused for example by Puccinia recondita;
Uromyces diseases caused for example by Uromyces appendicular^
Oomycete Diseases such as
Bremia diseases caused for example by Bremia lactucae
Peronospora diseases caused for example by Peronospora pisi and Peronospora brassicae
Phytophthora diseases caused for example by Phytophthora infestans
Plasmopara diseases caused for example by Plasmopara viticola
Pseudoperonospora diseases caused for example by Pseudoperonospora humuli and Pseudoperonospora cubensis
Pythium diseases caused for example by Pythium ultimum
Leafspot, Leaf blotch and Leaf Blight Diseases such as
Alternaria diseases caused for example by Alternaria solani
Cercospora diseases caused for example by Cercospora beticola
Cladiosporium diseases caused for example by Cladiosporium cucumerinum
Cochliobolus diseases caused for example by Cochliobolus sativus
(Conidiaform: Drechslera, Syn: Helminthosporium);
Colletotrichum diseases caused for example by Colletotrichum lindemuthianum Cycloconium diseases caused for example by Cycloconium oleaginum
Diaporthe diseases caused for example by Diaporthe cirri
Elsinoe diseases caused for example by Elsinoe fawcettii
Gloeosporium diseases caused for example by Gloeosporium laeticolor
Glomerella diseases caused for example by Glomerella cingulata
Guignardia diseases caused for example by Guignardia bidwellii
Leptosphaeria diseases caused for example by Leptosphaeria maculans
Magnaporthe diseases caused for example by Magnaporthe grisea
Mycosphaerella diseases caused for example by Mycosphaerella graminicola and Mycosphaerella fijiensis
Phaeosphaeria diseases caused for example by Phaeosphaeria nodorum
Pyrenophora diseases caused for example by Pyrenophora teres
Ramularia- diseases caused for example by Ramularia collo-cygni
Rhynchosporium diseases caused for example by Rhynchosporium secalis
Septoria diseases caused for example by Septoria apii;
Typhula diseases caused for example by Thyphula incarnata
Venruria diseases caused for example by Venturia inaequalis
Root- and Stem Diseases such as
Corticium diseases caused for example by Corticium graminearum
Fusarium diseases caused for example by Fusarium oxysporum
Gaeumannomyces diseases caused for example by Gaeumannomyces graminis
Rhizoctonia diseases caused for example by Rhizoctonia solani
Tapesia diseases caused for example by Tapesia acuformis Thielaviopsis diseases caused for example by Thielaviopsis basicola
Ear and Panicle Diseases including Maize cob such as
Alternaria diseases caused for example by Alternaria spp.
Aspergillus diseases caused for example by Aspergillus flavus Cladosporium diseases caused for example by Cladiosporium cladosporioides
Claviceps diseases caused for example by Claviceps purpurea
Fusarium diseases caused for example by Fusarium culmorum
Gibberella diseases caused for example by Gibberella zeae
Monographella diseases caused for example by Monographella nivalis Smut- and Bunt Diseases such as
Sphacelotheca diseases caused for example by Sphacelotheca reiliana
Tilletia diseases caused for example by Tilletia caries
Urocystis diseases Urocystis occulta
Ustilago diseases caused for example by Ustilago nuda; Fruit Rot and Mould Diseases such as
Aspergillus diseases caused for example by Aspergillus flavus
Botrytis diseases caused for example by Botrytis cinerea
Penicillium diseases caused for example by Penicillium expansum and Penicillium purpurogenum
Sclerotinia diseases caused for example by Sclerotinia sclerotiorum; Verticillium diseases caused for example by Verticillium alboatrum
Seed- and Soilborne Decay, Mould, Wilt, Rot and Damping-off diseases
Alternaria diseases caused for example by Alternaria brassicicola
Aphanomyces diseases caused for example by Aphanomyces euteiches Ascochyta diseases caused for example by Ascochyta lentis
Aspergillus diseases caused for example by Aspergillus flavus
Cladosporium diseases caused for example by Cladosporium herbarum
Cochliobolus diseases caused for example by Cochliobolus sativus (Conidiaform: Drechslera, Bipolaris Syn: Helminthosporium);
Colletotrichum diseases caused for example by Colletotrichum coccodes;
Fusarium diseases caused for example by Fusarium culmorum;
Gibberella diseases caused for example by Gibberella zeae;
Macrophomina diseases caused for example by Macrophomina phaseolina Monographella diseases caused for example by Monographella nivalis;
Penicillium diseases caused for example by Penicillium expansum
Phoma diseases caused for example by Phoma lingam
Phomopsis diseases caused for example by Phomopsis sojae;
Phytophthora diseases caused for example by Phytophthora cactorum; Pyrenophora diseases caused for example by Pyrenophora graminea
Pyricularia diseases caused for example by Pyricularia oryzae;
Pythium diseases caused for example by Pythium ultimum;
Rhizoctonia diseases caused for example by Rhizoctonia solani;
Rhizopus diseases caused for example by Rhizopus oryzae Sclerotium diseases caused for example by Sclerotium rolfsii;
Septoria diseases caused for example by Septoria nodorum;
Typhula diseases caused for example by Typhula incarnata;
Verticillium diseases caused for example by Verticillium dahliae Canker, Broom and Dieback Diseases such as
Nectria diseases caused for example by Nectria galligena
Blight Diseases such as
Monilinia diseases caused for example by Monilinia laxa
Leaf Blister or Leaf Curl Diseases including deformation of blooms and fruits such as
Taphrina diseases caused for example by Taphrina deformans
Decline Diseases of Wooden Plants such as
Esca disease caused for example by Phaeomoniella clamydospora and Phaeoacremonium aleophilum and Fomitiporia mediterranea
Diseases of Flowers and Seeds such as
Botrytis diseases caused for example by Botrytis cinerea
Diseases of Tubers such as
Rhizoctonia diseases caused for example by Rhizoctonia solani
Helminthosporium diseases caused for example by Helminthosporium solani
Diseases caused by Bacterial Organisms such as
Xanthomanas species for example Xanthomonas campestris pv. Oryzae
Pseudomonas species for example Pseudomonas syringae pv. Lachrymans
Erwinia species for example Erwinia amylovora
The compounds releated to this invention are preferably used to control the following soybean diseases:
Fungal Diseases of the Foliage, Upper Stems, Pods and Seeds for example
Alternaria leaf spot (Alternaria spec, atrans tenuissima), Anthracnose (Colletotrichum gloeosporoides dematium var. truncatum), Brown spot (Septoria glycines), Cercospora leaf spot and blight (Cercospora kikuchii), Choanephora leaf blight (Choanephora infundibulifera trispora (Syn.)), Dactuliophora leaf spot (Dactuliophora glycines), Downy Mildew (Peronospora manshurica), Drechslera blight (Drechslera glycini), Frogeye Leaf spot (Cercospora sojina), Leptosphaerulina Leaf Spot (Leptosphaerulina trifolii), Phyllostica Leaf Spot (Phyllosticta sojaecola), Pod and Stem Blight (Phomopsis sojae), Powdery Mildew (Microsphaera diffusa), Pyrenochaeta Leaf Spot (Pyrenochaeta glycines), Rhizoctonia Aerial, Foliage, and Web Blight (Rhizoctonia solani), Rust (Phakopsora pachyrhizi, Phakopsora meibomiae), Scab (Sphaceloma glycines), Stemphylium Leaf Blight (Stemphylium botryosum), Target Spot (Corynespora cassiicola)
Fungal Disease of the Roots and Lower Stems for example
Black Root Rot (Calonectria crotalariae), Charcoal Rot (Macrophomina phaseolina), Fusarium Blight or Wilt, Root Rot, and Pod and Collar Rot (Fusarium oxysporum, Fusarium orthoceras, Fusarium semitectum, Fusarium equiseti), Mycoleptodiscus Root Rot (Mycoleptodiscus terrestris), Neocosmospora (Neocosmopspora vasinfecta), Pod and Stem Blight (Diaporthe phaseolorum), Stem Canker (Diaporthe phaseolorum var. caulivora), Phytophthora Rot (Phytophthora megasperma), Brown Stem Rot (Phialophora gregata), Pythium Rot (Pythium aphanidermatum, Pythium irregulare, Pythium debaryanum, Pythium myriotylum, Pythium ultimum), Rhizoctonia Root Rot, Stem Decay, and Damping-Off (Rhizoctonia solani), Sclerotinia Stem Decay (Sclerotinia sclerotiorum), Sclerotinia Southern Blight (Sclerotinia rolfsii), Thielaviopsis Root Rot (Thielaviopsis basicola).
The fact that the active compound combinations are well tolerated by plants at the concentrations required for controlling plant diseases permits a treatment of entire plants (above-ground parts of plants and roots), of propagation stock and seed, and of the soil. The active compound combinations according to the invention can be used for foliar application or else as seed dressings.
The fact that the active compounds which can be used are well tolerated by plants at the concentrations required for controlling plant diseases permits a treatment of the seed. Accordingly, the active compounds according to the invention can be used as seed dressings.
A large part of the damage to crop plants which is caused by phytopathogenic fungi occurs as early as when the seed is attacked during storage and after the seed is introduced into the soil, during and immediately after germination of the plants. This phase is particularly critical since the roots and shoots of the growing plant are particularly sensitive and even minor damage can lead to the death of the whole plant. Protecting the seed and the germinating plant by the use of suitable compositions is therefore of particularly great interest.
The control of phytopathogenic fungi which damage plants post-emergence is carried out primarily by treating the soil and the above-ground parts of plants with crop protection agents. Owing to the concerns regarding a possible impact of crop protection agents on the environment and the health of man and animals, there are efforts to reduce the amount of active compounds applied.
These compositions include not only compositions which are ready to be applied to the plant or seed to be treated by means of a suitable device, such as a spraying or dusting device, but also concentrated commercial compositions which must be diluted before application to the crop.
The control of phytopathogenic fungi by treating the seeds of plants has been known for a long time and is subject-matter of continuous improvements. However, the treatment of seed frequently entails a series of problems which cannot always be solved in a satisfactory manner. Thus, it is desirable to develop methods for protecting the seed and the germinating plant which dispense with the additional application of crop protection agents after sowing or after the emergence of the plants or where additional applications are at least reduced. It is furthermore desirable to optimize the amount of active compound employed in such a way as to provide maximum protection for the seed and the germinating plant from attack by phytopathogenic fungi, but without damaging the plant itself by the active compound employed. In particular, methods for the treatment of seed should also take into consideration the intrinsic fungicidal properties of transgenic plants in order to achieve optimum protection of the seed and the germinating plant with a minimum of crop protection agents being employed.
The present invention therefore in particular also relates to a method for the protection of seed and germinating plants from attack by phytopathogenic fungi, by treating the seed with a composition according to the invention.
The invention likewise relates to the use of the compositions according to the invention for the treatment of seed for protecting the seed and the germinating plant from phytopathogenic fungi.
Furthermore, the invention relates to seed which has been treated with a composition according to the invention so as to afford protection from phytopathogenic fungi.
One of the advantages of the present invention is that the particular systemic properties of the compositions according to the invention mean that treatment of the seed with these compositions not only protects the seed itself, but also the resulting plants after emergence, from phytopathogenic fungi. In this manner, the immediate treatment of the crop at the time of sowing or shortly thereafter can be dispensed with.
Furthermore, it must be considered as advantageous that the mixtures according to the invention can also be employed in particular in transgenic seed.
The method of treatment according to the present invention is useful to treat propagation material such as tubers or rhizomes, but also seeds, seedlings or seedlings pricking out and plants or plants pricking out. This method of treatment can also be useful to treat the overground parts of the plant such as trunks, stems or stalks, leaves, flowers and fruits of the concerned plant.
Plants that can be protected by the method according to the invention can be legumes or non- leguminous plants.
Among the plants that can be protected by the method according to the present invention, mention may be made of cotton; flax; vine; fruit or vegetable crops such as Rosaceae sp. (for instance pip fruit such as apples and pears, but also stone fruit such as apricots, almonds and peaches), Ribesioidae sp., Juglandaceae sp., Betulaceae sp., Anacardiaceae sp., Fagaceae sp., Moraceae sp., Oleaceae sp., Actinidaceae sp., Lauraceae sp., Musaceae sp. (for instance banana trees and plantins), Rubiaceae sp., Theaceae sp., Sterculiceae sp., Rutaceae sp. (for instance lemons, oranges and grapefruit); Solanaceae sp. (for instance tomatoes), Liliaceae sp., Asteraceae sp. (for instance lettuces), Umbelliferae sp., Cruciferae sp., Chenopodiaceae sp., Cucurbitaceae sp., Papilionaceae sp. (for instance peas), Rosaceae sp. (for instance strawberries); mojor crops such as Graminae sp. (for instance maize, lawn or cereals such as wheat, rice, barley and triticale), Asteraceae sp. (for instance sunflower), Cruciferae sp. (for instance colza), Fabacae sp. (for instance peanuts), Papilionaceae sp. (for instance soybean), Solanaceae sp. (for instance potatoes), Chenopodiaceae sp. (for instance beetroots); horticultural and forest crops; as well as genetically modified homologues of these crops.
Among the legumes, mention may be made of soybean, pea, horse bean, groundnut, bean, lupin, alfalfa or clover.
In the context of the present invention, the composition according to the invention is applied to the seed either alone or in a suitable formulation. Preferably, the seed is treated in a state which is stable enough to avoid damage during treatment. In general, the seed may be treated at any point in time between harvest and sowing. The seed usually used has been separated from the plant and freed from cobs, shells, stalks, coats, hairs or the flesh of the fruits. Thus, for example, it is possible to use seed which has been harvested, cleaned and dried to a moisture content of below 15% by weight. Alternatively, it is also possible to use seed which, after drying, has, for example, been treated with water and then dried again.
When treating the seed, care must generally be taken that the amount of the composition according to the invention applied to the seed and/or the amount of further additives is chosen in such a way that the germination of the seed is not adversely affected, or that the resulting plant is not damaged. This must be borne in mind in particular in the case of active compounds which may have phytotoxic effects at certain application rates.
The compositions according to the invention can be applied directly, that is to say without comprising further components and without having been diluted. In general, it is preferable to apply the composition to the seed in the form of a suitable formulation. Suitable formulations and methods for the treatment of seed are known to the skilled worker and are described, for example, in the following documents: US 4,272,417 A, US 4,245,432 A, US 4,808,430 A, US 5,876,739 A, US 2003/0176428 Al, WO 2002/080675 Al, WO 2002/028186 A2.
The active compound combinations according to the invention are also suitable for increasing the yield of crops. In addition, they show reduced toxicity and are well tolerated by plants.
According to the invention, it is possible to treat all plants and parts of plants. Plants are to be understood here as meaning all plants and plant populations, such as desired and undesired wild plants or crop plants (including naturally occurring crop plants). Crop plants can be plants which can be obtained by conventional breeding and optimization methods or by biotechnological and genetic engineering methods or combinations of these methods, including the transgenic plants and including plant cultivars which can or cannot be protected by plant breeders' certificates. Parts of plants are to be understood as meaning all above-ground and below-ground parts and organs of plants, such as shoot, leaf, flower and root, examples which may be mentioned being leaves, needles, stems, trunks, flowers, fruit-bodies, fruits and seeds and also roots, tubers and rhizomes. Parts of plants also include harvested material and vegetative and generative propagation material, for example seedlings, tubers, rhizomes, cuttings and seeds.
The treatment of the plants and parts of plants according to the invention with the active compounds is carried out directly or by action on their environment, habitat or storage area according to customary treatment methods, for example by dipping, spraying, evaporating, atomizing, broadcasting, brushing-on and, in the case of propagation material, in particular in the case of seeds, furthermore by one- or multilayer coating. As already mentioned above, it is possible to treat all plants and their parts according to the invention. In a preferred embodiment, wild plant species and plant cultivars, or those obtained by conventional biological breeding, such as crossing or protoplast fusion, and parts thereof, are treated. In a further preferred embodiment, transgenic plants and plant cultivars obtained by genetic engineering, if appropriate in combination with conventional methods (Genetically Modified Organisms), and parts thereof, are treated. The term "parts" or "parts of plants" or "plant parts" has been explained above.
Particularly preferably, plants of the plant cultivars which are in each case commercially available or in use are treated according to the invention.
Depending on the plant species or plant cultivars, their location and growth conditions (soils, climate, vegetation period, diet), the treatment according to the invention may also result in superadditive ("synergistic") effects. Thus, for example, reduced application rates and/or a widening of the activity spectrum and/or an increase in the activity of the substances and compositions which can be used according to the invention, better plant growth, increased tolerance to high or low temperatures, increased tolerance to drought or to water or soil salt content, increased flowering performance, easier harvesting, accelerated maturation, higher harvest yields, better quality and/or a higher nutritional value of the harvested products, better storage stability and/or processability of the harvested products are possible which exceed the effects which were actually to be expected.
The transgenic plants or plant cultivars (i.e. those obtained by genetic engineering) which are preferably to be treated according to the invention include all plants which, in the genetic modification, received genetic material which imparted particularly advantageous useful properties ("traits") to these plants. Examples of such properties are better plant growth, increased tolerance to high or low temperatures, increased tolerance to drought or to water or soil salt content, increased flowering performance, easier harvesting, accelerated maturation, higher harvest yields, better quality and/or a higher nutritional value of the harvested products, better storage stability and/or processability of the harvested products. Further and particularly emphasized examples of such properties are a better defence of the plants against animal and microbial pests, such as against insects, mites, phytopathogenic fungi, bacteria and/or viruses, and also increased tolerance of the plants to certain herbicidally active compounds. Examples of transgenic plants which may be mentioned are the important crop plants, such as cereals (wheat, rice), maize, soya beans, potatoes, cotton, oilseed rape and also fruit plants (with the fruits apples, pears, citrus fruits and grapes), and particular emphasis is given to maize, soya beans, potatoes, cotton and oilseed rape. Traits that are emphasized are in particular increased defence of the plants against insects, by toxins formed in the plants, in particular those formed in the plants by the genetic material from Bacillus thuringiensis (for example by the genes CiyΙA(a), CryIA(b), CryΙA(c), CryllA, CrylllA, CryIIIB2, Cry9c, Cry2Ab, Cry3Bb and CryIF and also combinations thereof) (hereinbelow referred to as "Bt plants"). Traits that are furthermore particularly emphasized are the increased tolerance of the plants to certain herbicidally active compounds, for example imidazolinones, sulphonylureas, glyphosate or phosphinotricin (for example the "PAT" gene). The genes which impart the desired traits in question can also be present in combination with one another in the transgenic plants. Examples of "Bt plants" which may be mentioned are maize varieties, cotton varieties, soya bean varieties and potato varieties which are sold under the trade names YIELD GARD® (for example maize, cotton, soya beans), KnockOut® (for example maize), StarLink® (for example maize), Bollgard® (cotton), Nucoton® (cotton) and NewLeai® (potato). Examples of herbicide-tolerant plants which may be mentioned are maize varieties, cotton varieties and soya bean varieties which are sold under the trade names Roundup Ready® (tolerance to glyphosate, for example maize, cotton, soya bean), Liberty Link® (tolerance to phosphinotricin, for example oilseed rape), MI® (tolerance to imidazolinones) and STS® (tolerance to sulphonylureas, for example maize). Herbicide-resistant plants (plants bred in a conventional manner for herbicide tolerance) which may be mentioned also include the varieties sold under the name Clearfield® (for example maize). Of course, these statements also apply to plant cultivars which have these genetic traits or genetic traits still to be developed, and which will be developed and/or marketed in the future.
Depending on their particular physical and/or chemical properties, the active compound combinations according to the invention can be converted into the customary formulations, such as solutions, emulsions, suspensions, powders, dusts, foams, pastes, soluble powders, granules, aerosols, suspoemulsion concentrates, natural and synthetic materials impregnated with active compound and microencapsulations in polymeric substances and in coating compositions for seeds, and ULV cool and warm fogging formulations.
These formulations are produced in a known manner, for example by mixing the active compounds or active compound combinations with extenders, that is liquid solvents, liquefied gases under pressure, and/or solid carriers, optionally with the use of surfactants, that is emulsifiers and/or dispersants, and/or foam formers.
If the extender used is water, it is also possible to employ, for example, organic solvents as auxiliary solvents. Essentially, suitable liquid solvents are: aromatics such as xylene, toluene or alkylnaphthalenes, chlorinated aromatics or chlorinated aliphatic hydrocarbons such as chlorobenzenes, chloroethylenes or methylene chloride, aliphatic hydrocarbons such as cyclohexane or paraffins, for example petroleum fractions, mineral and vegetable oils, alcohols such as butanol or glycol and their ethers and esters, ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone or cyclohexanone, strongly polar solvents such as dimethylformamide or dimethyl sulphoxide, or else water. Liquefied gaseous extenders or carriers are to be understood as meaning liquids which are gaseous at standard temperature and under atmospheric pressure, for example aerosol propellants such as butane, propane, nitrogen and carbon dioxide.
Suitable solid carriers are: for example ammonium salts and ground natural minerals such as kaolins, clays, talc, chalk, quartz, attapulgite, montmorillonite or diatomaceous earth, and ground synthetic minerals such as finely divided silica, alumina and silicates. Suitable solid carriers for granules are: for example crushed and fractionated natural rocks such as calcite, pumice, marble, sepiolite and dolomite, or else synthetic granules of inorganic and organic meals, and granules of organic material such as sawdust, coconut shells, maize cobs and tobacco stalks. Suitable emulsifiers and/or foam formers are: for example nonionic and anionic emulsifiers, such as polyoxyethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, for example alkylaryl polyglycol ethers, alkylsulphonates, alkyl sulphates, arylsulphonates, or else protein hydrolysates. Suitable dispersants are: for example lignosulphite waste liquors and methylcellulose.
Tackifiers such as carboxymethylcellulose, natural and synthetic polymers in the form of powders, granules or latices, such as gum arabic, polyvinyl alcohol and polyvinyl acetate, or else natural phospholipids such as cephalins and lecithins and synthetic phospholipids can be used in the formulations. Other possible additives are mineral and vegetable oils.
It is possible to use colorants such as inorganic pigments, for example iron oxide, titanium oxide and Prussian Blue, and organic dyestuffs such as alizarin dyestuffs, azo dyestuffs and metal phthalocyanine dyestuffs, and trace nutrients such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc.
The formulations for controlling unwanted phytopathogenic fungi generally comprise between 0,00000000000001 (10"14) and 95 per cent by weight of active compound, preferably between 0,000000001 (10~9) and 90%.
The active compound combinations according to the invention can be used as such, in the form of their formulations or as the use forms prepared therefrom, such as ready-to-use solutions, emulsifiable concentrates, emulsions, suspensions, wettable powders, soluble powders, dusts and granules. They are used in a customary manner, for example by watering (drenching), drip irrigation, spraying, atomizing, broadcasting, dusting, foaming, spreading-on, and as a powder for dry seed treatment, a solution for seed treatment, a water-soluble powder for seed treatment, a water-soluble powder for slurry treatment, or by encrusting. The active compound combinations according to the invention can, in commercial formulations and in the use forms prepared from these formulations, be present as a mixture with other active compounds, such as insecticides, attractants, sterilants, bactericides, acaricides, nematicides, fungicides, growth regulators or herbicides.
When using the active compound combinations according to the invention, the application rates can be varied within a relatively wide range, depending on the kind of application. In the treatment of parts of plants, the application rates of active compound combination are generally between 10"6 g and 10 000 g/ha, preferably between 10"4 g and 1000 g/ha and more preferably between 10 g/lQQQ g/ha. In the treatment of seeds, the application rates of active compound combination are generally between 10"6 g and 50 g per kilogram of seed, preferably between 10"4 g and 10 g per kilogram of seed and more preferably between 0,01 g and 1O g per kg of seed. In the treatment of the soil, the application rates of active compound combination are generally between 10"6 g and 10 000 g/ha, preferably between 10"4 g and 5000 g/ha and more preferably between 1 g and 5000 g/ha.
The active compound combinations can be used as such, in the form of concentrates or in the form of generally customary formulations, such as powders, granules, solutions, suspensions, emulsions or pastes.
The formulations mentioned can be prepared in a manner known per se, for example by mixing the active compounds with at least one solvent or diluent, emulsifϊer, dispersant and/or binder or fixative, water repellent, if desired desiccants and UV stabilizers, and, if desired, colorants and pigments and other processing auxiliaries.
The inventive method for the protection of seeds and plants, arising from these seeds, against fungal diseases comprises a procedure in which the seed is treated at the same time with genistein of formula (I) and at least one fungicide selected from groups (2) to (24). It further comprises a method in which the seed is treated with genistein of formula (I) and at least one fungicide selected from groups (2) to (24) separately.
The invention also comprises a seed, which has been treated with genistein of formula (I) and at least one fungicide selected from groups (2) to (24) at the same time. The invention also comprises a seed, which has been treated with genistein of formula (I) and at least one fungicide selected from groups (2) to (24) separately. For such a seed, the active ingredients, can be applied in separate layers. These layers can optionally be separated by one or more additional layers that may or may not contain active ingredients. A mixture with other known active compounds, such as insecticides, herbicides, or with fertilizers and growth regulators, safeners and/or semiochemicals is also possible.
The good fungicidal activity of the active compound combinations according to the invention is evident from the example below. While the individual active compounds exhibit weaknesses with regard to the fungicidal activity, the combinations have an activity which exceeds a simple addition of activities.
A synergistic effect of fungicides is always present when the fungicidal activity of the active compound combinations exceeds the total of the activities of the active compounds when applied individually.
The expected activity for a given combination of two active compounds can be calculated as follows (cf. Colby, S. R., "Calculating Synergistic and Antagonistic Responses of Herbicide Combinations", Weeds 15, pages 20-22, 1967):
If
X is the efficacy, when applying the active compound A at a rate of application of active compound of m g/ha,
Y is the efficacy, when applying the active compound B at a rate of application of active compound of n g/ha,
E is the expected efficacy, when applying the active compounds A and B at rates of application of active compound of m and n g/ha,
X . Y then E = X + Y
100
The degree of efficacy, expressed in % is denoted. 0% means an efficacy which corresponds to that of the control while an efficacy of 100% means that no disease is observed.
If the actual fungicidal activity exceeds the calculated value, then the activity of the combination is superadditive, i.e. a synergistic effect exists. In this case, the efficacy which was actually observed must be greater than the value for the expected efficacy (E) calculated from the abovementioned formula.
The invention is illustrated by the following examples. The invention is illustrated by the following example.
Exemple
A) Rhizoctonia solani -Test (in vitro) / Microtest
The microtest was performed in liquid medium with potato-dextrose broth (PDB) using microtitre plates.
The active compound is applied as the technical active substance dissolved in methanol.
A mycelium suspension ol Rhizoctonia solani was used for inoculation. After 5 days of incubation by darkness under shaking (10 Hrz), the optical density m each cavity was evaluated with the aid of a microtitre plate reader.
0% means an efficacy which corresponds to that of the control, while an efficacy of 100% means that no fungal growth is observed.
The table below clearly shows that the observed activity of the active compound combination according to the invention is greater than the calculated activity, i.e. a synergistic effect is present.
Table A
Rhizoctonia solani -Test (in vitro) / Microtest
Figure imgf000116_0001
Inventive Compound combination:
Ratio of the Rate of application Actual Expected mixture of active Efficacy value, compound calculated in ppm (%) using Colby's formula
Pyflufen
+ } 10000:1 0.3 +
0.00003 } 68 60
Genistein
BL Gibberella zeae -Test (in vitro*) / Microtest
The microtest was performed in liquid medium with potato-dextrose broth (PDB) using microtitre plates.
The active compound is applied as the technical active substance dissolved in methanol.
A spore suspension of Gibberella zeae was used for inoculation. After 5 days of incubation by darkness under shaking (10 Hrz), the optical density in each cavity was evaluated with the aid of a microtitre plate reader.
0% means an efficacy which corresponds to that of the control, while an efficacy of 100% means that no fungal growth is observed.
The table below clearly shows that the observed activity of the active compound combination according to the invention is greater than the calculated activity, i.e. a synergistic effect is present.
Table B
Gibberella zeae -Test (in vitro") / Microtest
Figure imgf000118_0001
Inventive Compound combination:
Ratio of the Rate of Actual Expected value, mixture application of Efficacy calculated active using Colby's compound formula in ppm
Metalaxyl 10000:1 0.003 + 52 32 + 0.0000003 Genistein
O Rhizoctonia solani -Test (in vitro*) / Microtest
The microtest was performed in liquid medium with potato-dextrose broth (PDB) using microtitre plates.
The active compound is applied as the technical active substance dissolved in methanol.
A mycelium suspension of Rhizoctonia solani was used for inoculation. After 3 days of incubation by darkness under shaking (10 Hrz), the optical density in each cavity was evaluated with the aid of a microtitre plate reader.
0% means an efficacy which corresponds to that of the control, while an efficacy of 100% means that no fungal growth is observed.
The table below clearly shows that the observed activity of the active compound combination according to the invention is greater than the calculated activity, i.e. a synergistic effect is present.
Table C
Rhizoctonia solani -Test (in vitro) / Microtest
Figure imgf000120_0001
Inventive Compound combination:
Ratio of the Rate of application Actual Expected value, mixture of active Efficacy calculated compound (%) using Colby's in ppm formula
Metalaxyl ) 10000:1 0.01+
+ J 0.000001 } 95 62
Genistein
SI Coriolus versicolor -Test (in vitro) / Microtest
The microtest was performed in liquid medium with potato-dextrose broth (PDB) using microtitre plates.
The active compound is applied as the technical active substance dissolved in methanol.
A mycelium suspension of Coriolus versicolor was used for inoculation. After 3 days of incubation by darkness under shaking (10 Hrz), the optical density in each cavity was evaluated with the aid of a microtitre plate reader.
0% means an efficacy which corresponds to that of the control, while an efficacy of 100% means that no fungal growth is observed.
The table below clearly shows that the observed activity of the active compound combination according to the invention is greater than the calculated activity, i.e. a synergistic effect is present.
Table D
Coriolus versicolor -Test (in vitro) / Microtest
Figure imgf000122_0001
Inventive Compound combination:
Ratio of the Rate of Actual Expected value, mixture application of Efficacy calculated active compound using Colby's in ppm formula
Prothioconazole 10000:1 0.1 + 0.00001 91 85
+
Genistein
EL Botrytis cinerea -Test (in vitro) / Microtest
The microtest was performed in liquid medium with potato-dextrose broth (PDB) using microtitre plates.
The active compound is applied as the technical active substance dissolved in methanol.
A spore suspension of Botrytis cinerea was used for inoculation. After 5 days of incubation by darkness under shaking (10 Hrz), the optical density in each cavity was evaluated with the aid of a microtitre plate reader.
0% means an efficacy which corresponds to that of the control, while an efficacy of 100% means that no fungal growth is observed.
The table below clearly shows that the observed activity of the active compound combination according to the invention is greater than the calculated activity, i.e. a synergistic effect is present.
Table E
Botrytis cinerea -Test (in vitro) / Microtest
Figure imgf000124_0001
Inventive Compound combination:
Ratio of the Rate of Actual Expected value, mixture application of Efficacy calculated active (%) using Colby's compound formula in ppm
Trifloxystrobin 10000:1 0.03 + 19 + 0.000003 Genistein

Claims

Patent claims
1. Active compound combinations, comprising genistein of formula (I)
Figure imgf000126_0001
and at least one active compound selected from groups (2) to (24) below: Group (2) Strobilurins of the general formula (ID
Figure imgf000126_0002
in which
A represents one of the groups
Figure imgf000126_0003
A2 represents NH or O, A3 represents N or CH, L represents one of the groups
Figure imgf000126_0004
where the bond marked with an asterisk (*) is attached to the phenyl ring,
R11 represents phenyl, phenoxy or pyridinyl, each of which is optionally mono- or disubstituted by identical or different substituents from the group consisting of chlorine, cyano, methyl and trifluoromethyl, or represents l-(4-chlorophenyl)- pyrazol-3-yl or represents l,2-propanedione-bis(O-methyloxime)-l-yl,
R12 represents hydrogen or fluorine;
Group (3) Triazoles of the general formula (HT)
Figure imgf000127_0001
in which
Q represents hydrogen or SH,
m represents 0 or 1,
R13 represents hydrogen, fluorine, chlorine, phenyl or 4-chlorophenoxy,
R14 represents hydrogen or chlorine,
A4 represents a direct bond, -CH2-, -(CH2)2- or -O-,
A4 furthermore represents *-CH2-CHR17- or *-CH=CR17-, where the bond marked with * is attached to the phenyl ring, in which case R15 and R17 together represent -CH2-CH2-CH[CH(CH3)2]- or -CH2-CH2-C(CH3);,-,
A5 represents C or Si (silicon),
A4 further represents -N(R17)- and A5 furthermore together with R15 and R16 represents the group C=N-R18, in which case R17 and R18 together represent the group , where the bond marked with * is attached to R17,
Figure imgf000128_0001
R15 represents hydrogen, hydroxyl or cyano,
R16 represents 1 -cyclopropylethyl, 1 -chlorocyclopropyl, Ci-C4-alkyl, C1-C6- hydroxyalkyl, C1-C4-alkylcarbonyl, Ci-C2-haloalkoxy-Ci-C2-alkyl, trimethylsilyl- Ci-C2-alkyl, monofluorophenyl or phenyl,
R15 and R16 furthermore together represent -0-CH2-CH(R18)-O-, -0-CH2-CH(R18)-CH2-, or -O-CH-(2-chlorophenyl)-,
R18 represents hydrogen, Ci-C4-alkyl or bromine;
Group (4) Sulphenamides of the general formula (FV)
Figure imgf000128_0002
in which R19 represents hydrogen or methyl;
Group (5) Valinamides selected from
(5-1) iprovalicarb
(5-2) N'-[2-(4-{[3-(4-chlorophenyl)-2-propynyl]oxy}-3-methoxyphenyl)ethyl]-N2- (mcthylsulphonyl)-D-valinamide
(5-3) benthiavalicarb, Group (6) Carboxamides of the general formula (V)
Figure imgf000129_0001
in which
X represents 2-chloro-3-pyridinyl, represents l-methylpyrazol-4-yl which is substituted in the 3-position by methyl or trifluoromethyl and in the 5-position by hydrogen or chlorine, represents 4-ethyl-2-ethylamino-l,3-thiazol-5-yl, represents
1-methyl-cyclohexyl, represents 2,2-dichloro-l-ethyl-3-methylcyclopropyl, represents 2-fluoro-2 -propyl or represents phenyl which is mono- to trisubstituted by identical or different substituents from the group consisting of chlorine, methyl, and trifluoromethyl,
X furthermore represents 3,4-dichloroisothiazol-5-yl, 5, 6-dihydro-2 -methyl- 1,4- oxathiin-3-yl, 4-methyl-l,2,3-thiadiazol-5-yl, 4,5-dimethyl-2- trimethylsilylthiophen-3-yl, l-methylpyrrol-3-yl which is substituted in the
4-position by methyl or trifluoromethyl and in the 5-position by hydrogen or chlorine,
Y represents a direct bond, CrC6-alkanediyl (alkylene) which is optionally substituted b y chlorine, cyano or oxo or represents thiophenediyl,
Y furthermore represents Ca-Cβ-alkenediyl (alkenylene),
Z represents hydrogen or the group
Figure imgf000129_0002
Z furthermore represents Ci-C6-alkyl,
A6 represents CH or N, R20 represents hydrogen, chlorine, phenyl which is optionally mono- or disubstituted by identical or different substituents from the group consisting of chlorine and di(CrC3-alkyl)aminocarbonyl,
R20 furthermore represents cyano or d-C6-alkyl,
R21 represents hydrogen, chlorine, or 1-methylethoxy
R22 represents hydrogen, chlorine, hydroxyl, methyl or trifluoromethyl,
R22 furthermore represents di(CrC3-alkyl)aminocarbonyl,
R20 and R21 furthermore together represent *-CH(CH3)-CH2-C(CH3)2- or *-CH(CH3)-O-C(CH3)2- where the bond marked with * is attached to R20;
or the general formula (Va)
Figure imgf000130_0001
in which
R1 represents hydrogen, halogen, CVCa-alkyl or Ci-C3-haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,
A represents one of the radicals Al to A8 below:
Figure imgf000131_0001
R2 represents CrC3-alkyl,
R3 represents hydrogen, halogen, Ci-C3-alkyl or Ci-C3-haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,
R4 represents hydrogen, halogen or Ci-C3-alkyl,
R5 represents halogen, CrC3-alkyl or Ci-C3-haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,
R6 represents hydrogen, halogen, Ci-C3-alkyl, amino, mono- or di(CrC3- alkyl)amino,
R7 represents hydrogen, halogen, Ci-C3-alkyl or CrC3-haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,
R8 represents halogen, Ci-C3-alkyl or Ci-C3-haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms,
R9 represents halogen, Ci-C3-alkyl or CVQ-haloalkyl having 1 to 7 fluorine, chlorine and/or bromine atoms, R10 represents hydrogen, halogen, Ci-C3-alkyl or Ci-C3-haloalkyl having 1 to 7 f luorine, chlorine and/or bromine atoms,
Group (7) Dithiocarbamates selected from
(7-1) mancozeb
(7-2) maneb
(7-3) metiram
(7-4) propineb
(7-5) thiram
(7-6) zineb
(7-7) ziram
Group (8) Acylalanines of the general formula (VI)
Figure imgf000132_0001
in which
* marks a carbon atom in the R or the S configuration, preferably in the S configuration,
R23 represents benzyl, furyl or methoxymethyl; Group (9): Anilinopyrimi dines of the general formula (VIf)
Figure imgf000133_0001
in which
R24 represents methyl, cyclopropyl or 1-propynyl;
Group (10): Benzimidazoles of the general formula (VUT)
Figure imgf000133_0002
in which
R25 and R26 each represent hydrogen or together represent -0-CF2-O-,
R27 represents hydrogen, CrC4-alkylaminocarbonyl or represents 3,5- dimethylisoxazol-4-ylsulphonyl,
R28 represents chlorine, methoxycarbonylamino, chlorophenyl, furyl or thiazolyl;
Group (11): Carbamates of the general formula (DC)
Figure imgf000133_0003
in which
R29 represents n- or isopropyl,
R represents di(Ci-C2-alkyl)amino-C2-C4-alkyl or diethoxyphenyl, salts of these compounds being included;
Group (12): Dicarboximides selected from
(12-1) captafol
(12-2) captan (12-3) folpet
(12-4) iprodione
(12-5) procymidone
(12-6) vinclozolin
Group (13): Guanidines selected from (13-1) dodine
(13-2) guazatine
(13-3) iminoctadine triacetate
(13-4) iminoctadine tris(albesilate)
Group (14): Imidazoles selected from (14-1) cyazofamid
(14-2) prochloraz
(14-3) triazoxide
(14-4) pefurazoate Group (15): Morpholines of the general formula (X)
Figure imgf000135_0001
in which
R31 and R32 independently of one another represent hydrogen or methyl,
R33 represents Ci-Ci4-alkyl (preferably Ci2-Ci4-alkyl), C5-Ci2-cycloalkyl (preferably Cio-Ci2-cycloalkyl), phenyl-C1-C4-alkyl, which may be substituted in the phenyl moiety by halogen or CrC4-alkyl or represents acrylyl which is substituted by chlorophenyl and dimethoxyphenyl;
Group (16): Pyrroles of the general formula (XD
Figure imgf000135_0002
in which
R34 represents chlorine or cyano,
R35 represents chlorine or nitro,
R36 represents chlorine,
R35 and R36 furthermore together represent -Q-CF2-O-;
Group (17): Phosphonates selected from
(17-1) fosetyl-Al (17-2) phosphonic acid;
Group (18): Phenylethanamides of the general formula (XID
Figure imgf000136_0001
in which
R37 represents unsubstituted or fluorine-, chlorine-, bromine-, methyl- or ethyl- substituted phenyl, 2-naphthyl, 1,2,3,4-tetrahydronaphthyl or indanyl;
Group (19): Fungicides selected from
(19-1) acibenzolar-S-methyl
(19-2) chlorothalonil
(19-3) cymoxanil
(19-4) edifenphos
(19-5) famoxadone
(19-6) fluazinam
(19-7) copper oxychloride
(19-8) copper hydroxide
(19-9) oxadixyl
(19-10) spiroxamine
(19-l l) dithianon (19-12) metrafenone
(19-13) fenamidone
(19-14) 2,3-dibutyl-6-chlorothieno[2,3-d]pyrimidin-4(3H)-one
(19-15) probenazole
(19-16) isoprothiolane
(19-17) kasugamycin
(19-18) phthalide
(19-19) ferimzone
(19-20) tricyclazole
(19-21) N-( {4-[(cyclopropylamino)carbonyl]phenyl} sulphonyl)-2-methoxybenzamide
(19-22) 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-l-yloxy)phenyl]ethyl}-2-(prop- 2-yn- 1 -yloxy)acetamide
(19-23) Diclomezine
(19-24) Hymexazole
(19-25) Iprobenfos
(19-26) Triflumizole
Group (20): (Thio)urea derivatives selected from
(20-1) pencycuron
(20-2) thiophanate-methyl
(20-3) thiophanate-ethyl Group (21): Amides of the general formula (XIID
Figure imgf000138_0001
in which
A7 represents a direct bond or -O-,
A8 represents -C(=O)NH- or -NHC(=O)-,
R38 represents hydrogen or Ci-C4-alkyl,
R39 represents Ci-C6-alkyl;
Group (22): Triazolopyrimidines of the general formula (XIV)
Figure imgf000138_0002
in which
R40 represents Ci-C6-alkyl or C2-C6-alkenyl,
R41 represents CrC6-alkyl,
R40 and R41 furthermore together represent C4-C5-alkanediyl (alkylene) which is mono- or disubstituted by Ci-C6-alkyl,
R42 represents bromine or chlorine,
R43 and R47 independently of one another represent hydrogen, fluorine, chlorine or methyl, R44 and R46 independently of one another represent hydrogen or fluorine,
R45 represents hydrogen, fluorine or methyl,
Group (23): Iodochromones of the general formula (XV)
Figure imgf000139_0001
in which
R48 represents Ci-C6-alkyl,
R49 represents CrC6-alkyl, C2-C6-alkenyl or C2-C6-alkynyl;
Group (24): Biphenylcarboxamides of the general formula (XVD
Figure imgf000139_0002
in which
R represents hydrogen or fluorine,
R51 represents fluorine, chlorine, bromine, methyl, trifluoromethyl, trifluoromethoxy, -CH=N-OMe or -C(Me)=N-OMe,
R52 represents hydrogen, fluorine, chlorine, bromine, methyl or trifluoromethyl, Het represents one of the radicals Hetl to Het7 below:
Figure imgf000140_0001
Hetl Het2 Het3 Het4
Figure imgf000140_0002
Het5 Het6 Het7
R53 represents iodine, methyl, difluoromethyl or trifluoromethyl,
R54 represents hydrogen, fluorine, chlorine or methyl,
R55 represents methyl, difluoromethyl or trifluoromethyl,
R56 represents chlorine, bromine, iodine, methyl, difluoromethyl or trifluoromethyl,
R57 represents methyl or trifluoromethyl,
Active compound combinations according to Claim 1, where the active compounds of groups (2) to (24) are selected from the list below:
(2-1) azoxystrobin
(2-2) fluoxastrobin
(2-3) (2£)-2-(2-{[6-(3-chloro-2-methylphenoxy)-5-fluoro-4-pyrimidinyl]oxy}phenyl)-2- (methoxyimino)-N-methylethanamide
(2-4) trifloxystrobin (2-5) (2£)-2-(methoxyimino)-N-methyl-2-(2- { [( {( IE)- 1 -[3 -(trifluoromethyl)- phenyl]ethyliden}amino)oxy]methyl}phenyl)ethanamide
(2-6) (2£)-2-(methoxyimino)-N-methyl-2-{2-[(^)-({l-[3-(trifluoromethyl)phenyl]- ethoxy } imino)methyl]phenyl } ethanamide (2-7) orysastrobin
(2-8) 5-methoxy-2-methyl-4-(2-{[({(l£)-l-[3-(trifluoromethyl)phenyl]ethyliden}amino)- oxy]methyl}phenyl)-2,4-dihydro-3H-l,2,4-triazol-3-one
(2-9) kresoxim-methyl
(2-10) dimoxystrobin (2-11) picoxystrobin
(2-12) pyraclostrobin
(2-13) metominostrobin
(3-1) azaconazole
(3-2) etaconazole (3-3) propiconazole
(3-4) difenoconazole
(3-5) bromuconazole
(3-6) cyproconazole
(3-7) hexaconazole (3-8) penconazole
(3-9) myclobutanil (3-10) tetraconazole
(3-11) flutriafol
(3-12) epoxiconazole
(3-13) flusilazole (3-14) simeconazole
(3-15) prothioconazole
(3-16) fenbuconazole
(3-17) tebuconazole
(3-18) ipconazole (3-19) metconazole
(3-20) triticonazole
(3-21) bitertanol
(3-22) triadimenol
(3-23) triadimefon (3-24) fluquinconazole
(3-25) quinconazole
(4-1) dichlofluanid
(4-2) tolylfluanid
(5-1) iprovalicarb (5-3) benthiavalicarb (6- 1 ) 2-chloro-N-( 1 , 1 ,3-trimethylindan-4-yl)nicotinamide
(6-2) boscalid
(6-3) furametpyr
(6-4) N-(3-p-tolylthiophen-2-yl)-l-methyl-3-trifluoromethyl-lH-pyrazole-4-carboxamide
(6-5) ethaboxam
(6-6) fenhexamid
(6-7) carpropamid
(6-8) 2-chloro-4-(2-fluoro-2-methylpropionylamino)-N,N-dimethylbenzamide
(6-9) picobenzamid
(6-10) zoxamide
(6-11) 3,4-dichloro-N-(2-cyanophenyl)isothiazole-5-carboxamide
(6-12) carboxin
(6-13) tiadinil
(6-14) penthiopyrad
(6-15) silthiofam
(6-16) N-[2-(l,3-dimethylbutyl)phenyl]-l-methyl-4-(trifluoromethyl)-lH-pyrrole-3- carboxamide
(6-17) Ν-{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}-2- (trifluoromethyl)benzamide
(6a-8) 5-fluoro-l,3-dimethyl-N-[2-(l,3,3-trimethylbutyl)phenyl]-lH-pyrazole-4- carboxamide (6a-2) N-[pyflufen-2-(l,3-dimethylbutyl)phenyl]-5-fluoro-l,3-dimethyl-lH-pyrazole-4- carboxamide
(6a-16) N-[2-(l,3-dimethylbutyl)phenyl]-2-(trifluoromethyl)benzamide
(6a-13) N-[2-(l,3-dimethylbutyl)phenyl]-2-iodobenzamide
(6b-2) Ν-(2-[l,r-bicyclopropyl]-2-ylphenyl)-3-(difluoromethyl)-l-methyl-lΗ-pyrazole-4- carboxamide
(7-1) mancozeb
(7-2) maneb
(7-3) metiram
(7-4) propineb
(7-5) thiram
(7-6) zineb
(7-7) ziram
(8-1) benalaxyl
(8-2) furalaxyl
(8-3) metalaxyl
(8-4) metalaxyl-M
(8-5) benalaxyl-M
(9-1) cyprodinil
(9-2) mepanipyrim (9-3) pyrimethanil
(10-1) 6-chloro-5-[(3,5-dimethylisoxazol-4-yl)sulphonyl]-2,2-difluoro-5H- [ 1 , 3 Jdioxolo [4,5 -f]benzimidazole
(10-2) benomyl
(10-3) carbendazim
(10-4) chlorfenazole
(10-5) fuberidazole
(10-6) thiabendazole
(11-1) diethofencarb
(11-2) propamocarb
(11-3) propamocarb-hydrochloride
(11-4) propamocarb-fosetyl
(12-1) captafol
(12-2) captan
(12-3) folpet
(12-4) iprodione
(12-5) procymidone
(12-6) vinclozolin
(13-1) dodine
(13-2) guazatine (13-3) iminoctadine triacetate
(14-1) cyazofamid
(14-2) prochloraz
(14-3) triazoxide
(14-4) pefϊirazoate
(15-1) aldimorph
(15-2) tridemorph
(15-3) dodemorph
(15-4) fenpropimorph
(15-5) dimethomorph
(16-1) fenpiclonil
(16-2) fludioxonil
(16-3) pyrrolnitrin
(17-1) fosetyl-Al
(17-2) phosphonic acid
(18-1) 2-(2,3 -dihydro-1 H-inden-5 -yl)-N-[2-(3 ,4-dimethoxyphenyl)ethyl]-2- (methoxyimino)acetamide
(18-2) N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(methoxyimino)-2-(5,6,7,8-tetrahydro- naphthalen-2-yl)acetamide
(18-3) 2-(4-chlorophenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(methoxyimino)acetamide (18-4) 2-(4-bromophenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(methoxyimino)acetamide
(18-5) 2-(4-methylphenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2- (methoxyimino)acetamide
(18-6) 2-(4-ethylphenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(methoxyimino)acetamide
(19-1) acibenzolar-S-methyl
(19-2) chlorothalonil
(19-3) cymoxanil
(19-4) edifenphos
(19-5) famoxadone
(19-6) fluazinam
(19-7) copper oxychloride
(19-9) oxadixyl
(19-10) spiroxamine
(19-l l) dithianon
(19-12) metrafenone
(19-13) fenamidone
(19-14) 2,3-dibutyl-6-chlorothieno[2,3-d]pyrimidin-4(3H)-one
(19-15) probenazole
(19-16) isoprothiolane
(19-17) kasugamycin (19-18) phthalide
(19-19) ferimzone
(19-20) tricyclazole
( 19-21 ) N-( {4-[(cyclopropylamino)carbonyl]phenyl } sulphonyl)-2-methoxybenzamide
( 19-22) 2-(4-chlorophenyl)-N- {2-[3-methoxy-4-(prop-2-yn- 1 -yloxy)phenyl]ethyl } -2-(prop-
2-yn- 1 -yloxy)acetamide
(20-1) pencycuron
(20-2) thiophanate-methyl
(20-3) thiophanate-ethyl
(21-1) fenoxanil
(21-2) diclocymet
(22-1) 5-chloro-N-[f75>2,2,2-trifluoro-l-methylethyl]-6-(2,4,6-trifluoro- phenyl)[l,2,4]triazolo[l,5-a]pyrimidine-7-amine
(22-2) 5-chloro-N-[f7i?>l ,2-dimethylpropyl]-6-(2,4,6-trifluorophenyl)[l ,2,4]triazolo- [l,5-a]pyrimidine-7-amine
(22-3) 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4-methylpiperidin-l-yl)[l,2,4]triazolo- [1 ,5-a]pyrimidine
(22-4) 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-l-yl)[l,2,4]triazolo[l,5-a]- pyrimidine
(23-1) 2-butoxy-6-iodo-3-propylbenzopyran-4-one
(23-2) 2-ethoxy-6-iodo-3-propylbenzopyran-4-one
(23-3) 6-iodo-2-propoxy-3-propylbenzopyran-4-one (23-4) 2-but-2-ynyloxy-6-iodo-3-propylbenzopyran-4-one
(23-5) 6-iodo-2-( 1 -methylbutoxy)-3-propylbenzopyran-4-one
(23-6) 2-but-3-enyloxy-6-iodobenzopyran-4-one
(23-7) 3-butyl-6-iodo-2-isopropoxybenzopyran-4-one
(24- 1 ) N-(3 ',4'-dichloro-5-fluoro- 1 , 1 '-biphenyl-2-yl)-3 -(diΩuoromethyl)- 1 -methyl- IH- pyrazole-4-carboxamide
(24-2) 3-(difluoromethyl)-N-{3l-fluoro-41-[(J-?)-(methoxyimino)methyl]-l,l1-biphenyl-2- yl} - 1 -methyl- lH-pyrazole-4-carboxamide
(24-3) 3-(trifluoromethyl)-N-{3'-fluoro-4'-[(£)-(methoxyimino)methyl]-l,l'-biphenyl-2- yl}-l -methyl- lH-pyrazole-4-carboxamide
(24-4) N-(3',4'-dichloro-l,l'-biphenyl-2-yl)-5-fluoro-l,3-dimethyl-lH-pyrazole-4- carboxamide
(24-5) N-(4'-chloro-3 '-fluoro- 1 , 1 '-biphenyl-2-yl)-2-methyl-4-(trifluoromethyl)- 1 ,3- thiazole-5 -carboxamide
(24-6) N-(4'-chloro-l,l'-biphenyl-2-yl)-4-(difluoromemyl)-2-methyl-l,3-thiazole-5- carboxamide
(24-7) N-(4'-bromo-l,l'-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-l,3-thiazole-5- carboxamide
(24-8) 4-(difluoromethyl)-2-methyl-N-[4'-(trifluoromethyl)-l,l'-biphenyl-2-yl]-l,3- thiazole-5-carboxamide.
3. Use of active compound combinations according to Claim 1 or Claim 2 for controlling unwanted phytopathogenic fungi.
4. Use of active compound combinations according to Claim 1 or Claim 2 for treating plants, plant parts, or plant propagation material
5. Use of active Compound Combinations according to claim 1 or 2 for treating seed.
6. Use of active compound combinations according to Claim 4 or 5 for treating transgenic plants.
7. Use of active compound combinations according to any of Claims 4 to 6 for treating seed of transgenic plants.
8. Seed that has been treated with genistein and a fungicide selected from groups (2) to (24), according to Claim 1 or 2, either simultaneously or separately.
9. Method for controlling unwanted phytopathogenic fungi, characterized in that active compound combinations according to Claim 1 or 2 are applied to the unwanted phytopathogenic fungi and/or their habitat and/or seed.
10. Process for preparing fungicidal compositions, characterized in that active compound combinations according to Claim 1 or 2 are mixed with extenders and/or surfactants.
11. Method according to claim 9, characterized in that a seed is incubated or coated with, genistein and a fungicide selected from groups (2) to (24), at the same time.
12. Method according to claim 9, characterized in that a seed is incubated or coated with, genistein and a fungicide selected from groups (2) to (24), separately, optionally with at least one further separation layer between active ingredient layers.
PCT/EP2008/005746 2007-07-23 2008-07-15 Synergistic fungicidal active genistein combinations WO2009012907A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07112966 2007-07-23
EP07112966.2 2007-07-23

Publications (1)

Publication Number Publication Date
WO2009012907A1 true WO2009012907A1 (en) 2009-01-29

Family

ID=39967942

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/005746 WO2009012907A1 (en) 2007-07-23 2008-07-15 Synergistic fungicidal active genistein combinations

Country Status (2)

Country Link
AR (1) AR067523A1 (en)
WO (1) WO2009012907A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2272346A1 (en) 2009-07-08 2011-01-12 LANXESS Deutschland GmbH Penthiopyrad for protecting wood
WO2014078849A1 (en) * 2012-11-19 2014-05-22 Lonza, Inc. Succinate dehydrogenase inhibitor containing compositions
US20140378513A1 (en) * 2011-10-14 2014-12-25 Shapphire Energy, Inc. Use of fungicides in liquid systems
CN105028417A (en) * 2015-06-08 2015-11-11 柳州市天姿园艺有限公司 Composition for preventing and treating phytophthora root rot of cymbidium kanran

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087005A1 (en) * 2004-03-18 2005-09-22 Agribiotics Inc. Isoflavonoid compounds and use thereof
WO2008086948A1 (en) * 2007-01-16 2008-07-24 Syngenta Participations Ag Pesticidal combinations
WO2008092580A2 (en) * 2007-02-02 2008-08-07 Bayer Cropscience Ag Synergistic fungicidal combinations comprising formononetin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087005A1 (en) * 2004-03-18 2005-09-22 Agribiotics Inc. Isoflavonoid compounds and use thereof
WO2008086948A1 (en) * 2007-01-16 2008-07-24 Syngenta Participations Ag Pesticidal combinations
WO2008092580A2 (en) * 2007-02-02 2008-08-07 Bayer Cropscience Ag Synergistic fungicidal combinations comprising formononetin

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2272346A1 (en) 2009-07-08 2011-01-12 LANXESS Deutschland GmbH Penthiopyrad for protecting wood
US20140378513A1 (en) * 2011-10-14 2014-12-25 Shapphire Energy, Inc. Use of fungicides in liquid systems
EP3042562A1 (en) * 2012-11-19 2016-07-13 Arch Wood Protection, Inc. Succinate dehydrogenase inhibitor containing compositions
CN104981161A (en) * 2012-11-19 2015-10-14 拱门木材保护有限公司 Succinate dehydrogenase inhibitor containing compositions
JP2016505532A (en) * 2012-11-19 2016-02-25 アーチ ウッド プロテクション,インコーポレーテッド Composition containing succinate dehydrogenase inhibitor
WO2014078849A1 (en) * 2012-11-19 2014-05-22 Lonza, Inc. Succinate dehydrogenase inhibitor containing compositions
CN106577678A (en) * 2012-11-19 2017-04-26 拱门木材保护有限公司 Compositions containing succinate dehydrogenase inhibitors
AU2013344405B2 (en) * 2012-11-19 2017-06-29 Arch Wood Protection, Inc. Succinate dehydrogenase inhibitor containing compositions
EA028042B1 (en) * 2012-11-19 2017-09-29 Арч Вуд Протекшн, Инк. Succinate dehydrogenase inhibitor containing compositions
AU2013344405C1 (en) * 2012-11-19 2018-11-29 Arch Wood Protection, Inc. Succinate dehydrogenase inhibitor containing compositions
AU2017225057B2 (en) * 2012-11-19 2018-12-13 Arch Wood Protection, Inc. Succinate dehydrogenase inhibitor containing compositions
CN106577678B (en) * 2012-11-19 2020-02-07 拱门木材保护有限公司 Composition containing succinate dehydrogenase inhibitor
US10829648B2 (en) 2012-11-19 2020-11-10 Arch Wood Protection, Inc. Succinate dehydrogenase inhibitor containing compositions
CN105028417A (en) * 2015-06-08 2015-11-11 柳州市天姿园艺有限公司 Composition for preventing and treating phytophthora root rot of cymbidium kanran

Also Published As

Publication number Publication date
AR067523A1 (en) 2009-10-14

Similar Documents

Publication Publication Date Title
JP5101491B2 (en) Bactericidal active substance combination showing synergistic action
DK1802197T3 (en) FUNGICIDE COMBINATIONS OF ACTIVE SUBSTANCES
CA2611178C (en) Combinations comprising glufosinate and strobilurins
CA2541646C (en) Synergistic fungicidal active compound combinations
US8134012B2 (en) Synergistic fungicidal active compound combinations
CA2793014A1 (en) Fungicidal active ingredient combinations comprising fluoxastrobin
WO2009012907A1 (en) Synergistic fungicidal active genistein combinations
EP2001299A2 (en) Fungicidal active substance combinations
WO2007104437A1 (en) Fungicidal active ingredient combinations
CA2611159A1 (en) Fungicidal active substance combinations
DE102006014723A1 (en) Fungicide combinations useful for plant and material protection comprise a pyrazole carboxamide and at least one fungicide selected from 24 groups of compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08784759

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08784759

Country of ref document: EP

Kind code of ref document: A1